Q3 2023 Bio-Rad Laboratories Inc Earnings Call
Speaker 1: transcript
Speaker 1: To actively disengend the men, thank you for standing by. Welcome to the BiRAD third quarter, 2020 financial results, Conference call and webcast.
Good afternoon, ladies and gentlemen, thank you for standing by walking to the bio Rad third quarter 'twenty financial results conference call and webcast. At this time all lines are in a listen only mode. Following the presentation. We will conduct a question and answer session. If at any time during this call.
Speaker 1: transcript
Speaker 1: at this time, online turn on the machine only mode. Following the presentation, we will conduct a question in answer session.
Speaker 1: transcript
Speaker 1: If at any time during this call you require immediate assistance, please pass the SPAR 0 bird operator. And please be advised that the bird's call is being recorded on Thursday, October 26, 2023.
The required immediate assistance. Please press star zero for operator, and please be advised that today's call is being recorded on Thursday October 26th 2023.
Speaker 1: transcript
Speaker 1: I would now like to turn the conference over to Edward Schoen. Head of Investor Relations, please go ahead.
I would now like to turn the conference over to Edward Chang head.
Head of Investor Relations. Please go ahead.
Speaker 2: transcript
Speaker 2: Good afternoon, everyone. Thank you for joining us. Today we will review third quarter, 2023 financial results, and provide an update on key business trends for BIRAD.
Good afternoon, everyone and thank you for joining US today, we will review third quarter 2023 financial results and provide an update on key business trends for bio Rad.
Speaker 2: transcript
Speaker 2: With me on the call today are Norman Schwartz, our chief executive officer, Elon Dostoyl, executive vice president and chief financial officer, and the last executive vice president and chief operating officer, Simon May, president of the life science group and our right president of the clinical diagnostic group.
With me on the call today are Norman Schwartz, our Chief Executive Officer.
Ron Basso Executive Vice President and Chief Financial Officer, Andy last Executive Vice President and Chief Operating Officer, Simon May President of the life Science group and our Wright President of the clinical diagnostics group.
Speaker 2: transcript
Speaker 2: Before we begin our review, I'd like to caution everyone that we will be making forward-looking statements about management's goals, plans and expectations, our future financial performance, and other matters. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Our actual results may differ materially from these plans, goals, and expectations.
Before we begin our review I'd like to caution everyone that we will be making forward looking statements about managements goals plans and expectations, our future financial performance and other matters.
These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Our actual results may differ materially from these plans goals and expectations.
Speaker 2: transcript
Speaker 2: You should not place undue lines on these four looking statements and I encourage you to review our filings with the MBC where we discuss in detail the risk factors in our business. The company does not intend to update any four looking statements made during the call today.
You should not place undue reliance on these forward looking statements and I encourage you to review our filings with the SEC, where we discuss in detail the risk factors in our business. The company does not intend to update any forward looking statements made during the call today.
Speaker 2: transcript
Speaker 2: Finally, our remarks today will include references to non- GAAP financial s, including net income and deluded earnings per share, which are financial measures that are not defined under generally accepted accounting principles. Investors should review these recommendations of the non- GAAP financial measures to comparable gap results contained in our earnings release.
Finally, our remarks today will include references to non-GAAP financials, including net income and diluted earnings per share, which are financial measures that are not defined under generally accepted accounting principles investors should review. These reconciliations of the non-GAAP financial measures to comparable GAAP results contained in.
Our earnings release.
Speaker 2: transcript
Speaker 2: With that, I will now turn the call over to Annie Last, our Executive Vice President and Chief Operating Officer to provide an update on BioRads Global Operations.
With that I will now turn the call over to Andy last <unk>, Our executive Vice President and Chief operating officer to provide an update on bio rads global operations.
Hi, many thanks, Jay and good afternoon to everybody and thank you for joining us.
Speaker 3: transcript
Speaker 3: My many thanks, and good afternoon to everybody, and thank you for joining us.
Speaker 3: transcript
Speaker 3: Well, the third quarter of the year fell below our expectations. The ongoing challenges within the biopharmate segment and economic constraints in China continue to drive lower life sciences performance in the quarter.
Well the third quarter of the year fell below our expectations.
Challenges within the Biopharma segment and.
And economic constraints in China continued to drive lower life Sciences performance in the quarter.
Speaker 3: transcript
Speaker 3: Clinical diagnostic cells were weaker than we forecasted, impacted mainly by the softer China market.
Clinical diagnostic sales were weaker than we forecast it impacted mainly by the softer China market conditions.
Speaker 3: transcript
Speaker 3: We still anticipate a strong year over year growth, the clinical diagnostic group in the Fourth Court.
We still anticipate a strong year over year growth the clinical diagnostics group in the fourth quarter.
Speaker 3: transcript
Speaker 3: We continue to successfully maintain focus on high cost control. And on the supply chain front, we experience modest constraints in supply for our clinical business, which impacted Q3 sales.
We continued to successfully maintain focus on tight cost control and on the supply chain front, we experienced modest constraints in supply for our clinical business, which impacted Q3 sales.
Speaker 3: transcript
Speaker 3: Backflow remains on track to meet our year end expect.
Backlog remains on track to meet our year end expectations.
Speaker 3: transcript
Speaker 3: In Q3 we experienced furlough reduced demand from bi-farmer customers for our process chromatography resins and from both bi-farmants we will provide tech customers for our Lifeline 3 sector projects.
In Q3, we experienced further reduced demand from biopharma customers for our process chromatography resins and from both biopharm and smaller biotech customers for our life Science research projects products.
Speaker 3: transcript
Speaker 3: The continued tight spending environment in this segment can strengthen core DDPCR sales, which were roughly slapped on the year ago's very.
The continued tight spending environment in this segment constrained core DD PCR sales, which were roughly flat from the year ago period.
Academic and government sales for life Sciences was strong in the Americas.
Speaker 3: transcript
Speaker 3: Academic and government fails for life sciences were strong in the Americas.
Operator: Good afternoon ladies and gentlemen, thank you for standing by.
Speaker 3: transcript
Speaker 3: but shows decline in the impact driven down by China economic and policy.
Let's show declines in APAC, driven down by China, economic and policy constraints.
Operator: Welcome to the Bio Rad third quarter, 2020 financial results, conference call and webcast. At this time, online turn numbers in only mode.
Speaker 3: transcript
Speaker 3: Emeon academic fails were roughly flat, reflecting a soft funding environment in Germany, offset by stronger performance in the other Europe .
EMEA academic sales were roughly flat, reflecting a soft funding environment in Germany offset by stronger performance in the other European countries.
Operator: Following the presentation, we will conduct a question in answer session. If at any time during this call, you require immediate assistance, please pass a star zero or the operator. And these be advised that the day's call is being recorded on Thursday, October 26, 2023.
Speaker 3: transcript
Speaker 3: Well, DDPCR files within the quarter were softer than expected as a result of by far more spending.
While <unk> sales within the quarter was softer than expected as a result of biopharma spending.
Speaker 3: transcript
Speaker 3: We remain very positive on the long-term growth outlook for the platform.
We remain very positive on the long term growth outlook for the platform.
Edward Schoen: I would now like to turn the conference over to Edward Schoen, head of investor relations, please go ahead. Good afternoon everyone, thank you for joining us. Today we will review third quarter, 2023 financial results and provide an update on key business trends for Bio Rad. With me on the call today are Norman Schwartz, our chief executive officer, Ilan Daskal, executive vice president and chief financial officer, Andy Last, executive vice president and chief operating officer, Simon May, president of the life science group and our right president of the clinical diagnostics group.
Speaker 3: transcript
Speaker 3: During the quarter, we were encouraged by several no worthy announcements involving DVPCR.
During the quarter, we were encouraged by several noteworthy announcements involving Dv Pcr.
Speaker 3: transcript
Speaker 3: On the clinical testing front, our QX1 platform has been selected for estimate testing for all newborns in Hong Kong.
On the clinical testing front, our <unk> platform has been selected for SMA testing for all newborns in Hong Kong.
Speaker 3: transcript
Speaker 3: And here in the US, genoscopy announced they have published the results of their pivotal CRC prevent clinical trial, reporting the highest sensitivity for detecting colorectal cancer among similar tests.
And here in the U S. Gino Skippy announced they have published the results of the pivotal CRC prevent clinical trial reporting the highest sensitivity for detecting colorectal cancer among similar tests.
Speaker 3: transcript
Speaker 3: ? m2
Powered by our Q by Q, <unk> Dx DD Pcr platform.
Edward Schoen: Before we begin our review, I'd like to caution everyone that we will be making forward looking statements about management's goals, plans and expectations, our future financial performance and other matters. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Our actual results may differ materially from these plans, goals and expectations. You should not place undue lines on these forward looking statements and I encourage you to review our filings with the MBC where we discuss in detail the risk factors in our business.
Additionally, in the U S rarely won a major multiyear national wastewater testing contract from the CDC based on our Q X 600 platform.
Speaker 3: transcript
Speaker 3: Additionally in the US, rarely won a major multi-air national waste war to testing contract from the CDC based on our QX600 class.
Speaker 3: transcript
Speaker 3: We see these as contributors to future growth and a strong reinforcement of the versatility and impact of the tech.
We see these as contributors to future growth and a strong reinforcement of the versatility and impact of the technology.
Speaker 3: transcript
Speaker 3: As highlighted earlier, China was a continued challenging Q3 for our life sciences business and unfortunately the economic constraints have now also impacted our clinical diagnostics business which in the first half of the year has been a positive for us in this reason.
As highlighted earlier, China was a continued challenging Q3 for our life Sciences business and Unfortunately, the economic constraints are now also impacted our clinical diagnostics business, which in the first half of the year has been a positive for us in this region.
Edward Schoen: The company does not intend to update any forward looking statements made during the call today. Finally, our remarks today will include references to non-GAP financials including net income and deluded earnings per share, which are financial measures that are not defined under generally accepted accounting principles.
Speaker 3: transcript
Speaker 3: We have now further constrained our expectations for China for the year ends and looked to 2024 before we expect these vines of recovery.
We have now further constrained our expectations for China for the year end and look to 2024 before we expect to see signs of recovery.
Speaker 3: transcript
Speaker 3: Our clinical business overall had a mixed quarter. We saw growth in demand in the US and Europe as expected, which was partially offset by the trust boxes in China.
Our clinical business overall had a mixed quarter, we saw growth in demand in the U S and Europe as expected, which was partially offset by the softness in China.
Edward Schoen: Investors should review these recommendations of the non-GAP financial measures to comparable gap results contained in our earnings release.
Speaker 3: transcript
Speaker 3: In particular, we were pleased with the continued momentum for our immunohematology and diabetes franchises in the court.
In particular, we were pleased with the continued momentum for our immuno hematology and diabetes franchises in the quarter.
Andy Last: With that, I will now turn the call over to Andy Last, our executive vice president and chief operating officer to provide an update on Biorad's global operations. Hi, many thanks, and good afternoon to everybody and thank you for joining us.
Speaker 3: transcript
Speaker 3: Despite the market challenges of this year, we view our strategy framework as being very solid and our platforms and market opportunities as providing sustainable long-term growth.
Despite the market challenges that this year, we view our strategy framework as being very solid.
Our platforms in market opportunities as providing sustainable long term growth.
Andy Last: Well, the third quarter of the year fell below our expectations. The ongoing challenges within the biopharmate segment and economic constraints in China continue to drive lower life sciences performance in the quarter. Clinical diagnostic cells will weaken and we forecast it impacted mainly by the softer China market conditions. We still anticipate a strong year over year grows the clinical diagnostic group in the fourth quarter. We continue to successfully maintain focus on tight cost control and on the supply chain front we experience modest constraints in supply for our clinical business which impacted Q3 sales.
Speaker 3: transcript
Speaker 3: We continue to focus on driving and improving our execution and with completion of a single global instance of SAP have now completed a major component of operational improvement.
We continue to focus on driving and improving our execution and with completion of a single Global instance of SAP.
We have now completed a major component of operational improvement.
Speaker 3: transcript
Speaker 3: Looking to the end of the year, we continue to expect the bi-form and small bi-tech company turn down and ongoing constraints in China and Russia to impact the overall growth through our life sciences business.
Looking to the end of the year, we continue to expect the Biopharma and small biotech company to company turndown and ongoing constraints in China, and Russia to impact the overall growth through our life Sciences business.
Speaker 3: transcript
Speaker 3: Although we do expect to see sequentially improved sales in the final quarter of the day.
Although we do expect to see sequentially improved sales in the final quarter of the year.
Speaker 3: transcript
Speaker 3: We remain positive on the momentum and continued growth in the clinical diagnostics business although somewhat moderated by the greater market constraints in China as well as ongoing trade restrictions in Russia.
We remain positive on the momentum and continued growth in our clinical diagnostics business.
Andy Last: Backlog remains on track to meet our year end expectations. In Q3, we experience further reduced demand from biopharmate customers for our process chromatography resins and from both biopharmate and smaller biotech customers for our Lifeline Research Projects product. The continued tight spending environment in this segment can strengthen core DDPCR sales, which were roughly flat on the year ago period. Academic and government sales for life sciences were strong in the Americas, but showed declines in APAC driven down by China economic and policy constraints.
Although somewhat moderated by the greater market constraints in China, as well as ongoing trade restrictions in Russia.
Speaker 3: transcript
Speaker 3: Thank you and at this point I will now pass you to a land to review the finance.
Thank you and at this point I will now pass you to our land to review the financial results. Thank.
Speaker 4: transcript
Speaker 4: Thank you, Andy. Now I would like to review the results of the third quarter. Net sales for the third quarter of 2023 were $632.1 million, which is a decline of 7.1% on a reported basis, versus $680.8 million in Q3 of 2022, and a 7.9% decline on a current sea neutral.
Thank you Andy now I would like to review the results of the third quarter net sales for the third quarter of 2023 were $632 $1 million, which is a decline of seven 1% on a reported basis versus $688 million in Q3 of 2012.
Two and a seven 9% decline on a currency neutral basis.
Speaker 4: transcript
Speaker 4: The third quarter, Euro-Veer Revenue Decline, was primarily the result of ongoing weakness in the bio-farm and market.
Andy Last: Emea, academic sales were roughly flat, reflecting a soft funding environment in Germany, offset by stronger performance in the other European countries. While DDPCR sales within the quarter were softer than expected as a result of bioformer spending, we remained very positive on the long-term growth outlook for the platform. During the quarter, we were encouraged by several no-worthy announcements involving DDPCR. On the clinical testing front, our QX1 platform has been selected for SMA testing for all newborns in Hong Kong.
The third quarter year over year revenue decline was primarily the result of ongoing weakness in the Biopharma end markets impacting the sales of our life science tools and bio processing products.
Speaker 4: transcript
Speaker 4: impacting the sales of our Lifetime tools and bioprocessing products.
Speaker 4: transcript
Speaker 4: In addition, we experienced weaker demand in China as a result of the macroeconomic environment as well as the local maiden China initiative.
In addition, we experienced weaker demand in China as a result of the macroeconomic environment as well as the local median China initiatives.
Speaker 4: transcript
Speaker 4: COVID-related sales in Q3 were $300,000 versus about $17.2 million in Q3 last year.
Colby related sales in Q3 were $300000 versus about $17 $2 million in Q3 last year.
Speaker 4: transcript
Speaker 4: Core revenue which excludes COVID-related sales decreased 5.5% on a continuous rubble.
Core revenue, which excludes causes related sales decreased five 5% on a currency neutral basis.
Andy Last: And here in the US, Genoscopy announced they have published the results of their pivotal CRC prevent clinical trial, reporting the highest sensitivity for detecting colorectal cancer among similar tests powered by our QXDX DDPCR platform. Additionally, in the US, rarely won a major multi-air national waste war to testing contract from the CDC based on our QX600 platform. We see these as contributors to future growth and a strong reinforcement of the versatility and impact of the technologies.
Speaker 4: transcript
Speaker 4: On a geographic basis, currency neutral, European core revenue, decreased in Asia and Europe , partially offset by increased sales in the Americas.
On a geographic basis currency neutral year over year core revenue decreased in Asia, and Europe, partially offset by increased sales in the Americas.
Speaker 4: transcript
Speaker 4: Sales of the Lifelines Group in the third quarter of 2023 were 263.5 million dollars, compared to 317.9 million dollars in Q3 of 2022, which is a decline of 17.1 percent on a reported basis and a 17.8 percent decline on a currency neutral.
Sales of the life Science group in the third quarter of 2023 or $263 $5 million.
<unk> to $317 9 million in Q3 of 2022, which is a decline of 17, 1% on a reported basis.
The 17, 8% decline on a currency neutral basis.
Speaker 4: transcript
Speaker 4: Excluding COVID-related sales, the Lifescience Group, year-of-year currency neutral, core revenue, decreased 13.7%, and was primarily reasoned by lower sales of QPCR, process chromatography, Western blotting products, and about Fled, year-of-year GDPCR.
Andy Last: As highlighted earlier, China was a continued challenging Q3 for our life sciences business, and unfortunately, the economic constraints have now also impacted our clinical diagnostics business, which in the first half of the year has been a positive for us in this region. We have now further constrained our expectations for China for the year end and looked to 2024 before we expect these signs of recovery. Our clinical business overall had a mixed quarter.
Excluding COVID-19 related sales the life Science group year over year currency neutral core revenue decreased 13, 7% and was primarily driven by lower sales of <unk> PCR process chromatography, Western blotting products and about flat year over year <unk> revenue.
Speaker 4: transcript
Speaker 4: Excluding process chromatographic sales, the underlying lifestyle business decreased 16.7% on a current sea neutral basis versus Q3 of 2020.
Excluding process chromatography sales the underlying life science business decreased 16, 7% on a currency neutral basis versus Q3 of 2022.
Andy Last: We saw growth in demand in the US and Europe as expected, which was partially offset by the softness in China. In particular, we were pleased with the continued momentum for our immunochematology and diabetes franchises in the quarter.
Speaker 4: transcript
Speaker 4: The Lifetime Group revenue, excluding process chromatography and COVID-related sales, decreased 11.6% on a current senior's rub.
The life Science group revenue, excluding process chromatography, and Covid related sales decreased 11, 6% on a currency neutral basis.
On a geographic basis life science year over year core revenue decreased in Asia, and Europe, partially offset by a modest increase sales in the Americas.
Speaker 4: transcript
Speaker 4: On a geographic basis, like science, zero-year core revenue, decreased in Asia and Europe , partially offset by modest increased sales in the Americas.
Andy Last: Despite the market challenges of this year, we view our strategy framework as being very solid and our platforms and market opportunities as providing sustainable long-term growth. We continue to focus on driving and improving our execution, and with completion of a single global instance of SAP, has now completed a major component of operational improvement. Looking to the end of the year, we continue to expect the biopharm and small biotech company turn down and ongoing constraints in China and Russia to impact the overall growth for our life sciences business, although we do expect to see sequentially improved sales in the final quarter of the year. We remain positive on the momentum and continued growth in the clinical diagnostics business, although somewhat moderated by the greater market constraints in China as well as ongoing trade restrictions in Russia.
Sales of the clinical diagnostics group in the third quarter were $368 1 million compared to $361 9 million in Q3 of 2022, a growth of one 7% on a reported basis and a 1% growth on it.
Speaker 4: transcript
Speaker 4: Sales of the clinical diagnostics group in the third quarter were 368.1 million dollars compared to 361.9 million dollars in Q3 of 2022 or growth of 1.7% on a reported basis and a 1% growth on a currency neutral basis.
Currency neutral basis.
Speaker 4: transcript
Speaker 4: Core clinical diagnosis year-of-year revenue, which excludes COVID-related sales, increased 1.4% on a currency neutral base.
Core clinical diagnostics year over year revenue, which excludes corporate related sales increased one 4% on a currency neutral basis.
Growth of the clinical diagnostics group was primarily driven by blood typing and diabetes products as well as growth from our quality controls portfolio.
Speaker 4: transcript
Speaker 4: Growth of the Clinical Diagnostic Group was primarily driven by blood typing and diabetes products as well as growth from our quality control support.
Speaker 4: transcript
Speaker 4: On a geographic basis, the Diagnostics Group posted currency neutral year-of-year co-revenue growth in the Americas and Europe , partially offset by the decline in age.
On a geographic basis, the diagnostics group posted currency neutral year over year core revenue growth in the Americas, and Europe, partially offset by the decline in Asia.
Ilan Daskal: Thank you, and at this point, I will now pass you to a land to review the financial results. Thank you, Andy. Now I would like to review the results of the third quarter. Net sales for the third quarter of 2023 were $632.1 million, which is a decline of 7.1% on a reported basis versus 680.8 million dollars in Q3 of 2022, and a 7.9% decline on a currency neutral basis. The third quarter of the year of the year revenue decline was primarily the result of ongoing weakness in the biopharma end markets, impacting the sales of our lifestyles and bioprocessing products.
Speaker 4: transcript
Speaker 4: The reported gross margin for the third quarter of 2023 was 53.1% on a gap basis and compares to 54.7% in Q3 of 2020.
The reported gross margin for the third quarter of 2023 was 53, 1% on a GAAP basis and compares to 54, 7% in Q3 of 2022.
Speaker 4: transcript
Speaker 4: The year of year growth margin decline was mainly due to unfavorable product mix, lower manufacturing volumes.
The year over year gross margin decline was mainly due to unfavorable product mix lower manufacturing volumes higher.
Speaker 4: transcript
Speaker 4: Higher material cost and inventory reserves and was partially offset by improved logistics costs.
Higher material costs and inventory reserves and was partially offset by improved logistics costs.
Speaker 4: transcript
Speaker 4: A monetization related to prior acquisitions recorded in cost of goods sold was $4.5 million compared to $4.4 million in Q3 of 2020.
Amortization related to prior acquisitions recorded in cost of goods sold was $4 5 million compared to $4 4 million in Q3 of 2022.
Speaker 4: transcript
Speaker 4: Third quarter operating expenses benefited from our cost-cutting initiatives, as well as a contingent consideration benefit of $18.9 million from last year's acquisition of Curiosity Dynamics.
Ilan Daskal: In addition, we experienced weaker demand in China as a result of the macroeconomic environment, as well as the local made-in-China initiatives. COVID-related sales in Q3 were $300,000 versus about $17.2 million in Q3 last year. Co-revenue, which excludes COVID-related sales, decreased 5.5% on a currency neutral basis. On a geographic basis, currency neutral, year-of-year co-revenue, decreased in Asia and Europe, partially offset by increased sales in the Americas. Sales of the lifestyles group in the third quarter of 2023 were $263.5 million, compared to $317.9 million in Q3 of 2022, which is a decline of 17.1% on a reported basis, and a 17.8% decline on a currency neutral basis.
Third quarter operating expenses benefited from our cost cutting initiatives.
As a contingent consideration benefit of $18 9 million.
From last year's acquisition of curiosity diagnostics.
Speaker 4: transcript
Speaker 4: SCNX Census for Q3 of 2023 worth $201.2 million, or 31.8% of sales, compared to $211.1 million, in Q3 of 2020.
SG&A expenses for Q3 of 2023 was $201 2 million.
Or 31, 8% of sales compared to $211 1 million or 31% in Q3 of 2022.
Speaker 4: transcript
Speaker 4: The lower SGNA in the quarter included $4.1 million in contingent consideration benefit that I mentioned earlier, as well as lower employee related.
The lower SG&A in the quarter included $4 $1 million in contingent consideration benefit as I mentioned earlier as well as lower employee related expenses.
Speaker 4: transcript
Speaker 4: Total amortization expense related to acquisition recorded in HGNA for the quarter was $1.6 million versus $1.8 million in Q3 of 2020.
Total amortization expense related to acquisitions recorded in SG&A for the quarter was $1 6 million versus.
<unk> was $1 $8 million in Q3 of 2022.
Speaker 4: transcript
Speaker 4: Research and development expense in the third quarter was $43.5 million or 6.9% of sales, compared to $66.8 million or 9.8% of sales in Q3 of 2020.
Research and development expense in the third quarter was $43 5 million.
Or six 9% of sales compared to $66 8 million or nine 8% of sales in Q3 of 2022.
Ilan Daskal: Excluding COVID-related sales, the lifestyles group, year-of-year currency neutral, co-revenue, decreased 13.7% and was primarily reasoned by lower sales of QPCR, process chromatography, western-blooding products, and about Fled, year-of-year GDPCR revenue. Excluding process chromatography sales, the underlying lifestyles business, decreased 16.7% on a currency neutral basis, versus Q3 of 2022. The lifestyles group revenue, excluding process chromatography and COVID-related sales, decreased 11.6% on a currency neutral basis. On a geographic basis, lifestyles, year-of-year co-revenue, decreased in Asia and Europe, partially offset by modest increased sales in the Americas.
Speaker 4: transcript
Speaker 4: The significantly lower R&D expenses recorded in the third quarter include a $14.8 million in contingent consideration benefit that I mentioned earlier, as well as lower projects and employee related.
This significantly lower R&D expenses recorded in the third quarter included $14 $8 million in contingent consideration benefit that I mentioned earlier as well as lower project and employee related expenses.
Q3, operating income was $99 million or.
Speaker 4: transcript
Speaker 4: Q3 operating income was $90.9 million or 14.4% of sales compared to $94.6 million or 13.9% of sales in Q3 of 2020.
Or 14, 4% of sales compared to $94 6 million.
13, 9% of sales in Q3 of 2022.
Speaker 4: transcript
Speaker 4: Looking below the operating line, the change in fair market value of equity security holdings, which are substantially related to the bio-reconagy of Sartorius AG shares, added 36.4 million dollars of income to the reported results.
Looking below the operating line the change in fair market value of equity security holdings, which are substantially related to BIOLASE ownership of Sartorius AG shares.
At $36 4 million of income to the reported results.
Ilan Daskal: Sales of the clinical diagnostics group in the third quarter were $368.1 million, compared to $361.9 million in Q3 of 2022, or growth of 1.7% on a reported basis, and a 1% growth on a currency neutral basis. Core clinical diagnostics year-of-year revenue, which excludes COVID-related sales, increased 1.4% on a currency neutral basis. Cases. Growth of the Clinical Diagnostic Group was primarily driven by blood typing and diabetes products, as well as growth from our quality control portfolio.
Speaker 4: transcript
Speaker 4: During the quarter, interest and other income resulted in net other income of $9.7 million Compared to net other expense of $13 million last year Primarily, driven by increased interest income from in the
During the quarter interest and other income resulted in net other income of $9 7 million.
Compared to net other expense of $13 million last year, primarily driven by increased interest income from investments.
The effective tax rate for the third quarter of 2023 was 22, 5% compared to 21, 5% in Q3 of last year.
Speaker 4: transcript
Speaker 4: The FHD stat rate for the third quarter of 2023 was 22.5%, compared to 21.5% in Q3 of last.
Speaker 4: transcript
Speaker 4: The effective tax rate this quarter was primarily affected by an unrealized gain in equity securities.
The effective tax rate this quarter was primarily affected by an unrealized gain in equity securities.
Speaker 4: transcript
Speaker 4: And the tax rates reported in Q3 of 2022 was primarily affected by an unrealized loss in it.
And the tax rate reported in Q3 of 2022 was primarily affected by an unrealized loss in equity securities.
Ilan Daskal: On a geographic basis, the Diagnostic Group hosted currency neutral year-of-year co-revenue growth in the Americas and Europe, partially offset by the decline in Asia. The reported growth margin for the third quarter of 2023 was 53.1% on a gap basis and compares to 54.7% in Q3 of 2022. The year-of-year growth margin decline was mainly due to unfavorable product mix, lower manufacturing volumes, higher material cost and inventory reserves and was partially offset by improved logistics costs.
Speaker 4: transcript
Speaker 4: Reported net income for the third quarter was $106.3 million or $3.64 the looted earnings per share compared to a loss of $162.8 million or $5.48 the looted loss per share in Q3 of 2020.
Reported net income for the third quarter was $106 3 million or $3 64 diluted earnings per share compares to a loss of $162 8 million or $5 48 diluted loss per share in Q3 of 2022.
Speaker 4: transcript
Speaker 4: This change from last year is largely related to changes in the valuation of the Sultorious Honour Chief executive vice mainsACHO.
This change from last year is largely related to changes in the valuation of the Sartorius holdings.
Moving on to the non-GAAP results.
Speaker 4: transcript
Speaker 4: Looking at the results on a non-gay basis, we have excluded certain atypical and unique items. The impacted both the gross and operating margins, as well as other in...
Looking at our results on a non-GAAP basis, we have excluded certain <unk> and unique items that impacted both the gross and operating margins as well as other income these.
Ilan Daskal: Amortization related to prior acquisitions recorded in cost of goods sold was $4.5 million compared to $4.4 million in Q3 of 2022. Third quarter operating expenses benefited from our cost-cutting initiatives as well as a contingent consideration benefit of $18.9 million from last year's acquisition of curiosity diagnostics. SUNX Census for Q3 of 2023 was $201.2 million or 31.8% of sales compared to $211.1 million or 31% in Q3 of 2022. The lower SUNA in the quarter included $4.1 million in contingent consideration benefit that I mentioned earlier as well as lower employee related expenses.
Speaker 4: transcript
Speaker 4: These items are detailed in the reconfiliation table in the press release.
These items are detailed in the reconciliation table in the press release.
Speaker 4: transcript
Speaker 4: Looking at the non-gear results for the third quarter, in cost of goods sold, we have excluded $4.5 million of amoralization of purchasing tentables, and a small restructuring gets...
Looking at the non-GAAP results for the third quarter in cost of goods sold we have excluded $4 $5 million of amortization of purchased intangibles and small restructuring expense.
Speaker 4: transcript
Speaker 4: These exclusions moved the gross margin from 53.1% for the third quarter of 2023 to a non-gay gross margin of 53.9% versus 55.6% in Q3 of 2020.
These exclusions moved the gross margin from 53, 1% for the third quarter of 2023 to our non-GAAP gross margin of 53, 9% versus 55, 6% in Q3 of 2022.
non-GAAP SG&A in the third quarter of 2023 was 31, 7% versus 30% in Q3 of 2022.
Speaker 4: transcript
Speaker 4: No one gets S-GNA in the third quarter of 2023 was 31.7% versus 30% in Q3 of 2020.
Speaker 4: transcript
Speaker 4: In SNA, on a non-gay basis, we have excluded $4.1 million of an acquisition related to the contingent consideration benefit mentioned earlier.
In SG&A on a non-GAAP basis, we have excluded $4 1 million.
If an acquisition related to the contingent consideration benefit mentioned earlier.
Ilan Daskal: Total amortization expense related to acquisition recorded in SUNA for the quarter was $1.6 million versus $1.8 million in Q3 of 2022. Research and development expense in the third quarter was $43.5 million or 6.9% of sales compared to $66.8 million or 9.8% of sales in Q3 of 2022. The significantly lower R&D expenses recorded in the third quarter included $14.8 million in contingent consideration benefit that I mentioned earlier as well as lower project and employee related expenses.
Speaker 4: transcript
Speaker 4: And in vitro diagnostic registration fee in Europe for previously approved products of $1.9 million.
And in vitro diagnostic registration fee in Europe for previously approved products of $1 $9 million.
Speaker 4: transcript
Speaker 4: Amolization of purchased intensible, so $1.6 million.
Amortization of purchased intangibles of $1 6 million.
Speaker 4: transcript
Speaker 4: and 1.3 million dollars of restructuring related.
And $1 3 million of restructuring related expenses.
Speaker 4: transcript
Speaker 4: Non-Get R&D in the third quarter of 2023 was 9.2% versus 9.7% in Q3 of 2020.
non-GAAP R&D in the third quarter of 2023 was nine.
Nine 2% versus nine 7% in Q3 of 2022.
Speaker 4: transcript
Speaker 4: In R&D, on a non-gave basis, we have excluded $14.8 million of an acquisition related to the contingent consideration benefit mentioned earlier, and a small restructuring
In R&D on a non-GAAP basis.
This $14 $8 million soften acquisition related to the contingent consideration benefit mentioned earlier.
And a small restructuring benefits.
Ilan Daskal: Q3 operating income was $90.9 million or 14.4% of sales compared to $94.6 million or 13.9% of sales in Q3 of 2022. Looking below the operating line, the change in fair market value of equity security holdings, which are substantially related to buy a red phonology of Sartorius AG shares added $36.4 million of income to the reported results. During the quarter, interest in other income resulted in net other income of $9.7 million compared to net other expense of $13 million last year.
The cumulative sum of these non-GAAP adjustments result in moving the quarterly operating margin from 14, 4% on a GAAP basis.
Speaker 4: transcript
Speaker 4: The cumulative sum of these non-get adjustments results in moving the quarterly operating margin from 14.4% on a gap basis to 12.9% on a non-get.
12.9% on a non-GAAP basis.
Speaker 4: transcript
Speaker 4: This non-get operating margin compares to a non-get operating margin of 15.8% in Q3 of 2020.
These non-GAAP operating margin compares to a non-GAAP operating margin of 15, 8% in Q3 of 2022.
Speaker 4: transcript
We have also excluded certain items below the operating line, which are the increasing value of the sartorius equity securities and loan receivable holdings of $36 $4 million.
Speaker 4: transcript
Speaker 4: $2.5 million gain from the release of an escrow for an acquisition.
$2 5 million gain from the release of an escrow for an acquisition.
Speaker 4: transcript
Speaker 4: And about a $700,000 loss that's all created we venture in.
And about a $700000 loss associated with venture investments.
Ilan Daskal: Primarily, driven by increased interest in income from any of the Dismanse. The FFD stat rate for the third quarter of 2023 was 22.5%, compared to 21.5% in Q3 of last year. The FFD stat rate of this quarter was primarily affected by an unrealized gain in equity securities, and the tax rates reported in Q3 of 2022 was primarily affected by an unrealized loss in equity securities.
The non-GAAP effective tax rate for the third quarter of 2023 was 23, 9% compared to 21, 7% for the same period in 2022.
Speaker 4: transcript
Speaker 4: The non-get effective structure rate for the third quarter of 2023 was 23.9% compared to 21.7% for the same period in 2020.
Speaker 4: transcript
Speaker 4: The higher rate in 2023 was driven by geografit or mix of earnings and reduced compensation related data.
Higher rates in 2023 was driven by geographical mix of earnings and reduced compensation related deductions.
Speaker 4: transcript
Speaker 4: We continue to estimate the full year non-gab tax rate to be between 22 and 23%.
We continue to estimate the full year non-GAAP tax rate to be between 22 and 23%.
Ilan Daskal: Reported net income for the third quarter was 106.3 million, or $3.64 diluted earnings per share, compared to a loss of 162.8 million, or $5.48 diluted loss per share in Q3 of 2022. This change from last year is largely related to changes in the valuation of the sectoral economics.
Speaker 4: transcript
Speaker 4: And finally, non-get 19 come for the third quarter of 2023, was $68.1 million, or $2.33 diluted earnings per share, compared to $79.2 million, or diluted earnings per share of $2.64 in Q3 of 2022.
And finally non-GAAP net income for the third quarter of 2023 was $68 1 million.
Or $2 33 diluted earnings per share compared to $79 2 million or diluted earnings per share of $2 64 in Q3 of 2022.
Moving on to the balance sheet.
Speaker 4: transcript
Speaker 4: During the third quarter, we purchased 58,478 shares of our stock at an average share price of $364.61 for a total cost of $21.3 million.
During the third quarter, we purchased 58478 shares of our stock.
Ilan Daskal: Moving on to the non-gift results. Looking at the results on a non-gift basis, we have excluded certain atypical and unique items that impacted both the growth and operating margins, as well as other income. These items are detailed in the reconciliation table in the press release. Looking at the non-gift results for the third quarter, in cost of goods sold, we have excluded $4.5 million of amortization of purchased intentables, and a small restructuring expense.
As an average share price of $364 61.
For a total cost of $21 3 million.
Speaker 4: transcript
Speaker 4: We still have nearly $480 million remaining in our board authorized share repurchase program and plan to continue with our opportunistic approach to buy the spark of our capital allocation.
We still have nearly $480 million remaining in our board authorized share repurchase program.
And plan to continue with our opportunistic approach to buybacks as part of our capital allocation strategy.
Total cash and short term investments at the end of Q3 was $1 billion and $765 million.
Speaker 4: transcript
Speaker 4: Total cash and short term investments at the end of Q3 was $1 billion and $765 million compared to $1 billion and $728 million at the end of Q2 of 2020.
Ilan Daskal: These exclusions moved the growth margin from 53.1% for the third quarter of 2023, to a non-gift growth margin of 53.9%, versus 55.6% in Q3 of 2022. Non-gift SGNA in the third quarter of 2023 was 31.7%, versus 30% in Q3 of 2022. In SGNA, on a non-gift basis, we have excluded $4.1 million of an acquisition related to the contingent consideration benefit mentioned earlier, and in vitro diagnostic registration fee in Europe for previously approved products of $1.9 million, amortization of purchased intentables of $1.6 million, and $1.3 million of restructuring related expenses.
<unk>, two $1 billion and $728 million at the end of Q2 of 2023.
The increase in cash and short term investments from the second quarter was primarily due to changes in working capital.
Speaker 4: transcript
Speaker 4: The increasing cash and short-term investment from the second quarter was primarily due to changes in working.
Speaker 4: transcript
Speaker 4: Inventory at the end of Q3 was $775.8 million, which is slightly lower than the inventory in the prior coin.
Inventory at the end of Q3 was $775 8 million.
It is slightly lower than the inventory in the prior quarter.
Speaker 4: transcript
Speaker 4: For the third quarter of 2023, net cash generated from operating activities was $97.7 million, which compares to $11 million in Q3 of 2022.
For the third quarter of 2023 net cash generated from operating activities was $97 7 million, which compares to $11 million in Q3 of 2022.
Speaker 4: transcript
Speaker 4: This increase mainly reflects changes in working capital and income tax pay.
This increase mainly reflects changes in working capital and income tax payments.
The adjusted EBITDA for the third quarter of 2023 was $112 7 million or 17, 8% of sales.
Speaker 4: transcript
Speaker 4: The adjusted EBDA for the third quarter of 2023 was $112.7 million or 17.8% of sales.
Ilan Daskal: Non-gift R&D in the third quarter of 2023 was 9.2%, versus 9.7% in Q3 of 2022. In R&D on a non-gift basis, we have excluded $14.8 million of an acquisition related to the contingent consideration benefit mentioned earlier, and a small restructuring benefit. The cumulative sum of these non-gift adjustments result in moving the quarterly operating margin from 14.4% on a-gift basis to 12.9% on a non-gift basis. This non-gift operating margin compares to a non-gift operating margin of 15.8% in Q3 of 2022.
Speaker 4: transcript
Speaker 4: The adjusted EB-DIMQ3 of 2022 was $135.7 million or 19.9%.
The adjusted EBITDA in Q3 of 2022 was $135 7 million or 19, 9% of sales.
Speaker 4: transcript
Speaker 4: Net capital expenditures for the third quarter of 2023 were $44 million and depreciation and amortization for the third quarter was $37.3 million.
Net capital expenditures for the third quarter of 2023 were $44 million and depreciation and amortization for the third quarter was $37 3 million.
Moving on to the non-GAAP guidance.
Speaker 4: transcript
Speaker 4: Even the current market environment, we are revising our 2023 financial outlook this
Given the current market environment, we are revising our 2023 financial outlook as follows.
Speaker 4: transcript
Speaker 4: We now have spent about 3.5% currency neutral year-over-year revenue decline in 2023, versus a growth of about 80 basis points previous-
We now expect about a three 5% currency neutral year over year revenue decline in 2023 versus a growth of about 80 basis points previously.
Ilan Daskal: We have also excluded certain items below the operating line, which are the increasing value of the Sartorius equity securities and the long-receivable holdings of $36.4 million. Cross, $2.5 million gain from the release of an escrow for an acquisition, and about a $700,000 loss associated with venture investments. The known yet effective tax rate for the third quarter of 2023 was 23.9%, compared to 21.7% for the same period in 2022. The higher rate in 2023 was driven by geographic mix of earnings and reduced compensation related deductions.
Speaker 4: transcript
Speaker 4: For the full year, we estimate currency neutral, year-to-year revenue growth, excluding COVID-related sales to be between zero and 50 basis points, versus about 4.5% in our prior days.
For the full year, we estimate currency neutral year over year revenue growth, excluding COVID-19 related sales to be between zero and 50 basis points.
This is about four 5% in our prior guidance.
Of the 400 to 450 basis points core revenue guide down too.
Speaker 4: transcript
Speaker 4: Over 400 to 450 base response core revenue guide down.
Speaker 4: transcript
Speaker 4: 250 basis points are related to the third quarter resume shortfall of which approximately 200 basis points is related to weakness in bioforma. And remaining 50 basis points related to lower clinical diagnostics say.
250 basis points are related to the third quarter revenue shortfall.
Approximately 200 basis points is related to weakness in Biopharma and remaining 60 basis points related to lower clinical diagnostic sales.
The remaining 150 to 200 basis points reduction is attributed to reduce process chromatography and other biopharma demand as well as continued softness in China.
Speaker 4: transcript
Speaker 4: The remaining 150 to 200 basis points reduction is attributed to reduced process chromatography and other biopharmadimem, as well as continued softness in child.
Ilan Daskal: We continue to estimate the full-year non-gift tax rate to be between 22 and 23%. And finally, non-gift income for the third quarter of 2023 was $68.1 million or $2.33 cents diluted earnings per share, compared to $79.2 million or diluted earnings per share of $2.64 in Q3 of 2022.
Speaker 4: transcript
Speaker 4: For the Lifetime Group, we expect about a 12% currency neutral revenue decline for 2023.
For the life Science group, we expect about a 12% currency neutral revenue decline for 2023.
Speaker 4: transcript
Speaker 4: And when excluding COVID-related sales, the Lifetime Group, Currently Neutral Revenue Decline, is projected to be between four and five percent.
And when excluding corporate related sales the life Science group currency neutral revenue decline is projected to be between four and 5%.
Speaker 4: transcript
Speaker 4: Extruding COVID and process chromatography related cells, Lifeline's group revenue is expected to decline between two and three percent.
Excluding Colgate and process chromatography related sales life Science group revenue is expected to decline between two and 3%.
Ilan Daskal: Moving on to the balance sheet. During the third quarter, we purchased 58,478 shares of our stock at an average share price of $364.61 for a total cost of $21.3 million. We still have nearly $480 million remaining in our board authorized share repurchase program and plan to continue with our opportunistic approach to buy back a spark of our capital allocation strategy. Total cash and short-term investments at the end of Q3 was $1.765 million compared to $1.728 million at the end of Q2 of 2023.
Speaker 4: transcript
Speaker 4: For the Diagnostics Group, while we remain encouraged with the overall demand, we are now guiding whole revenue growth to be about 4.5% versus 5.5% pre-
For the diagnostics group, while we remain encouraged with the overall demand. We are now guiding core revenue growth to be about four 5% versus five 5% previously.
Speaker 4: transcript
Speaker 4: Full year-known growth margin is now projected to be about 54% versus about 64.5% previously reflecting our updated expectation of sheath in product mix and volume.
Full year non-GAAP gross margin is now projected to be about 54%.
About 64, 5% previously, reflecting our updated expectation of shift in product mix and volume.
Speaker 4: transcript
Speaker 4: We now project full year-known guest operating margin to be about 14.5% versus approximately 16% in our prior guidance as we continue to carefully manage discretionary.
We now project full year non-GAAP operating margin to be about 14, 5%.
Approximately 16% in our prior guidance as we continue to carefully manage discretionary expenses.
Ilan Daskal: The increase in cash and short-term investment from the second quarter was primarily due to changes in working capital. Inventory at the end of Q3 was $775.8 million which is slightly lower than the inventory in the prior quarter. For the third quarter of 2023, net cash generated from operating activities was $97.7 million which compares to $11 million in Q3 of 2022. This increase mainly reflects changes in working capital and income tax payments. The adjusted EBDA for the third quarter of 2023 was $112.7 million or $17.8% of sales. The adjusted EBDA in Q3 of 2022 was $135.7 million or $19.9% of sales.
Speaker 4: transcript
Speaker 4: And full year adjusted EB-DAM margin is expected between 20 and 20.5% versus about 21.5% in our prior guide.
And full year adjusted EBITDA margin is expected to be between 20 and 25%.
Versus about 21, 5% in our prior guidance.
Speaker 5: transcript
Speaker 5: And now I'll turn the code over to Norma for a few remarks. Norma. Thank you, Elon. So I guess I just wanted to take a minute here to really to recognize Elon and his contributions over the last several years. It's part of our transformation. Elon has been a very valued member of the team, kind of working to improve financial planning and reporting processes.
Now I'll turn the call over to Norman for a few remarks. Thank.
Thank you Elon.
So I.
I guess I just wanted to take a minute here to to really to recognize Elon and his contributions over the last several years.
As part of our transformation Elon has been a very valued member of the team kind of working to improve our financial planning and reporting processes.
Speaker 5: transcript
Speaker 5: as well as to enhance the company's external profile with financial community.
As well as to enhance the company's external profile with the financial community.
Speaker 5: transcript
Speaker 5: I think we all very much appreciate as guidance and contributions, which do position us well for our continuing transformation.
And I think we all very much appreciate his guidance and contributions, which which do position us well for our continuing transformation.
Speaker 5: transcript
Speaker 5: As you might imagine, we have initiated a search for a successor. And in the meantime, you know, we have a strong, capable team who can manage very well in the interim.
As you might imagine we have initiated a search for his successor.
Ilan Daskal: Net capital expenditures for the third quarter of 2023 were $44 million and depreciation and moving on to the non-get guidance. Even the current market environment, we are revising our 2023 financial outlook this following. We now have spent about a 3.5% currency neutral year-over-year revenue decline in 2023 versus a growth of about 80 basis points previously. For the full year, we estimate currency neutral year-over-year revenue growth, excluding COVID-related sales to be between zero and 50 basis points versus about 4.5% in our prior guidance.
In the meantime, we have a strong capable team.
Who can manage very well in the interim.
Speaker 5: transcript
Speaker 5: So maybe while I have the floor, or maybe a closing comment about this year, certainly it's not unfolded the way we, or many of our peers first envisioned it. Kind of coming out of the pandemic, I think it has been challenging to predict the pace of recovery or market normalization, really all exacerbated by inflation. We've not seen in 20 years geopolitical events and of course the biopharmad disruption.
So maybe we'll address before maybe a closing comment about this year certainly it's not unfolded the way, we bore or many of our peers first envision that kind of coming out of the pandemic I think it has been challenging to predict.
The pace of recovery or market normalization.
Really all exacerbated by by inflation, we have not seen in 20 years geopolitical events.
And of course, the Biopharma disruption.
Speaker 5: transcript
Speaker 5: Think if I think about it a little bit, I think what we can be confident of is that our markets are buoyant.
Thank you.
Think about it a little bit I think what we can be contracted as I said our markets are buoyant.
Speaker 5: transcript
Speaker 5: and I feel the outlook is positive. There could always be a few more bumps in the road in the near term, but I do feel the company is really as well positioned and navigate what might come our way.
And.
I feel the outlook is positive.
Ilan Daskal: Of the 400 to 450 basis points core revenue guide down, 250 basis points are related to the third quarter revenue shortfall of which approximately 200 basis points is related to weakness in bioforma and remaining 50 basis points related to lower clinical diagnostic sales. The remaining 150 to 200 basis points reduction is attributed to reduced process chromatography and other bioforma demand as well as continued softness in China. For the Lifetime Group, we expect about a 12% currency neutral revenue decline for 2023 and when excluding COVID-related sales, the Lifetime Group currency neutral revenue decline is projected to be between 4 and 5%.
There could always be a few more bumps in the road in the near term, but I do feel the company is.
It really is well positioned to navigate what might come our way.
Speaker 5: transcript
Speaker 5: And just maybe to reemphasize a point that Andy made, you know, longer term or strategy and vision for the future, really has not changed.
And just maybe to reemphasize a point that Andy made longer term, our strategy and vision for the future.
It really has not changed.
Speaker 5: transcript
Speaker 5: With that operator, I think we'll open the line up to questions.
With that.
Operator, I think we will open the lineup for questions.
Speaker 1: transcript
Speaker 1: Thank you and ladies and gentlemen, we will begin the question and answer session.
Thank you and ladies and gentlemen.
The question and answer session.
Speaker 1: transcript
Speaker 1: Should you have a question, please press the star, followed by the number one on your cell phone keypad. You will hear a three-tone prompt acknowledging your request and your questions will be pulled in the order they are received. Should you wish to decline the form of the calling process, please press the star followed by the number two. And if you're using a speaker phone, please speak the handset before pressing any keys. One moment please for your first question.
So do you have a question. Please press the star followed they did everyone on your telephone keypad.
Are you looking at data problems acknowledging your request and your question to be pulled into order day RBC.
Ilan Daskal: Excluding COVID and process chromatography related sales, Lifetime Group revenue is expected to decline between 2 and 3%. For the diagnostics group, while we remain encouraged with the overall demand, we are now guiding core revenue growth to be about 4.5% versus 5.5% previously. Full year-known growth margin is now projected to be about 54% versus about 64.5% previously, reflecting our updated expectation of shifts in product mix and volume. We now project full year-known growth operating margin to be about 14.5% versus approximately 16% in our prior guidance as we continue to carefully manage discretionary expenses. Full year-adjusted EB-DOM margin is expected between 20 and 20.5% versus about 21.5% in our prior guidance.
Should you wish to decline to confirming the calling process.
Press the star followed by Tim Mchugh.
And if youre using a speakerphone, please speak to handset before pressing.
One moment. Please for your first question.
Speaker 1: transcript
Speaker 1: Your first question comes from the mind of Brandon Goulard from Japey's Your Line is open.
Your first question comes from the line of Brandon Couillard from Jefferies. Your line is open.
Hey, Thanks, good afternoon.
I'm not sure. If this is another question for Andy are alive, but the magnitude of the guidance reset and lifesciences relative to where you started the year.
Speaker 6: transcript
Speaker 6: I'm not sure if this is another question for Andy or Alon. But the magnitude of the guidance reset in life sciences relative to where you started the year.
Speaker 6: transcript
Speaker 6: the most dramatic of any of your peers by far.
It's the most dramatic of any of your peers by far.
Speaker 6: transcript
Speaker 6: Interesting to be such an inability to accurately forecast the business and the advance trends and how do we assess whether this is in fact a market dynamic as opposed to
One is you seem to be such a the ability to accurately forecast the business and demand trends.
And how do we assess whether this is in fact, a market dynamic as opposed to potential share losses.
Speaker 3: transcript
Speaker 3: Could you just say that the very last piece of game, Verendon, didn't catch your very last few words?
Could you just say the very large PC game branded didn't catch the very last few words.
Speaker 6: transcript
Speaker 6: I was saying how do we assess whether this is in fact a market dynamic versus potential share losses and what.
Yeah, Okay, and how do we assess whether this is in fact, a market dynamic versus potential share losses.
Norman Schwartz: I'll turn the code over to Norman for a few remarks. Thank you, Elon. I just wanted to take a minute here to really recognize Elon and his contributions over the last several years. As part of our transformation, Elon has been a very valued member of the team, working to improve financial planning and reporting processes, as well as to enhance the company's external profile with the financial community. I think we all very much appreciate his guidance and contributions, which do position as well for our continuing transformation.
Okay.
Speaker 3: transcript
Speaker 3: Look, I think that we came out of 2022 with really good trajectory and
Look I think that we came out of 2022 with really good trajectory and.
Speaker 3: transcript
Speaker 3: The effects that some companies had seen particularly in bioprocessing.
The effects that some companies have seen particularly in bio processing.
Speaker 3: transcript
Speaker 3: We're not showing up for us. And I think that's something that we communicated at the end of the first quarter that wasn't surprised.
We're not showing up for us and I think that's something that we communicated at the end of <unk>.
The first quarter, but that was a surprise.
Speaker 3: transcript
Speaker 3: and it took a while within 2023 for those effects to really roll out into
And.
It took a while within 2023 for those effects to really rollouts into into our funnel and start to experience the deferred.
Speaker 3: transcript
Speaker 3: into our final and start to experience the deferred.
Norman Schwartz: As you might imagine, we have initiated a search for his successor, and in the meantime, we have a strong, capable team who can manage very well in the interim. So maybe while I have the floor, or maybe a closing comment about this year, certainly it's not unfolded the way we, or many of our peers first envisioned it. Kind of coming out of the pandemic, I think it has been challenging to predict the pace of recovery or market normalization, really all exacerbated by inflation, we've not seen in 20 years geopolitical events, and of course the biopharma disruption.
Speaker 3: transcript
Speaker 3: orders being pushed out. But in the other factor that no one anticipated and which was meaningful for us.
Orders being pushed out.
Other facts.
But no one anticipated.
And which was meaningful for us.
Norman Schwartz: I think if I think about it a little bit, I think what we can be confident of is that our markets are buoyant, and I feel the outlook is positive, there could always be a few more bumps in the road in the near term, but I do feel the company is really as well positioned and navigate what might come our way, and just maybe to reemphasize a point that Andy made, longer term or strategy and vision for the future, really has not changed.
Speaker 3: transcript
Speaker 3: was the Silicon Valley bank collapse and the knock on effects of that, which really impacted the spending of pro-violet of the smaller biotech companies. And we've had significant trajectory in the smaller biotech.
Was the Silicon Valley Bank.
And our collapse and the knock on effects of that which.
It really impacted the spending profile of the smaller biotech companies and we've had significant trajectory in the smaller biotechs.
Speaker 3: transcript
Speaker 3: for in particular a drop of visual PCR, platform which also had some halo effect around it. So, you know, I think it took a couple of quarters for those effects to really materialize for us because our profiles are little different to some of the other plays.
In particular, our droplet digital PCR platform, which also has some halo effect around it so.
I think it took a couple of quarters for those effects to really materialize for us.
Those are profiles, a little different to some of the other players.
Speaker 3: transcript
Speaker 3: So that's how I view it and then of course since then Spending is not improved or to push out that continued and it's very difficult to to gauge you know the true inflection point right now and I think that's probably
So that's how I view it and then of course since then spending has not improved.
Order push outs have continued.
And it's very difficult to gauge.
True inflection point right now.
Think that's probably probably.
Speaker 3: transcript
Speaker 3: Probably a message is coming across broadly from other players in the category as well.
Our message is coming across broadly from other <unk>.
Players in the category as well.
Speaker 7: transcript
Speaker 7: This is Simon, maybe I'll just add for that as well because as we look at our funnels and we look at our wind-loss ratios across the portfolio.
This is Simon maybe I'll, just ask it off as well because as we look at our funnels and we look at our win loss ratios across the portfolio.
Operator: With that operator, I think we'll open the line up to questions. Thank you, and ladies and gentlemen, we will begin the question in as the session.
Speaker 7: transcript
Speaker 7: Whether you're talking about Western Blot or gene expression or digital PCR or our bioprocessed business.
What are you talking about western blot or gene expression or digital PCR or our bioprocess business, we really don't see any significant shifts I mean, obviously the conditions and shine or a biopharma have really deteriorated the feedstock that we consistently get from the field just thought there's still a high level of it.
Speaker 7: transcript
Speaker 7: We really don't see any significant shifts there. Obviously the conditions in China and by far more have really deteriorated. But the feedback that we consistently get from the field is that there's still a high level of interest in the products. The products that we've launched have been really well received. And again, the funnel dynamics in terms of when loss ratios are not seeing any significant shifts.
Operator: Should you have a question, please press this star, followed by the number one on your cell phone keypad. You will hear a three-tone prompt acknowledging your request and your questions will be pulled in the order they are received. Should you wish to decline the form of the calling process, these presses are followed by the number two.
Trusted in the products the products that we've launched it being really well received and again the funnel dynamics in terms of win loss ratios are not see any significant shifts. So we really do believe that this is a bunch of transient effects to other compounds agonist Nike proved very difficult year, but I don't think any macro.
Operator: And if you are using a speaker phone, please speed the hands up before pressing any key. One moment please for your first question.
Speaker 7: transcript
Speaker 7: So we really do believe that this is a bunch of transient effects that are compounding and it's making for a very difficult year. But I don't think there are any macro shifts in our competitive positioning in life science.
Brandon Collard: Your first question comes from the line of Brandon Collard from Jeffree, if your line is open. Thanks, good afternoon. I'm sure this is another question for Andy or Alon, but the magnitude of the guidance reset in life sciences, relative to where you started the year, is the most dramatic of any of your peers by far.
Shifts in our competitive positioning in life Sciences.
Okay.
Speaker 6: transcript
Speaker 6: Alon, I think the revised guide implies four-q revenue steps up to about 700 million, I believe.
I think the.
We revised guide implied for Q revenue stepped up to about 700 million I believe.
Speaker 6: transcript
Speaker 6: Q is usually very strong for biorepubision a normal environment either. So how do you risk is that revenue outlook? What are some of the variables that can swing at target for doubt?
Q is usually seasonally very strong for bio Rad, but this isn't a normal environment either so.
Andy Last: What does this seem to be such an inability to accurately forecast the business and the advancements? And how do we assess whether this is, in fact, a market dynamic as opposed to potential share losses in life sciences? Look, I think that we came out of 2022 with really good trajectory and the effects that some companies had seen, particularly in bioprocessing, were not showing up for us. And I think that's something that we communicated at the end of the first quarter, that was a surprise.
Is that revenue outlook or some of the variables that could swing that target for Gallagher.
Keeping in mind.
Speaker 3: transcript
Speaker 3: So, Sandy, the variables that might swing that, I think they're the same that we're, you know, the variables would really be, you know, the same that we're experiencing, just a little bit more acute, if China gets definitively worse than the trajectories on, for example.
So savi.
The variables that in my script that I think they have a saying that where the variables would really be the <unk>.
But we're experiencing just a little bit more acute in.
China get definitively worse and the trajectory itself for example.
Speaker 3: transcript
Speaker 3: That was, you know, we're back in the media really pulled back from spending. That could have an effect.
That was our way of academia really pulled back from spending.
That could have an effect.
Speaker 3: transcript
Speaker 3: You know, we're not expecting a Q4 budget flush this year. That's not in our thinking. You know, if that is realises that's good news, but we're not planning on that.
We're not expecting a Q4 budget flush this year, that's not in our thinking.
If that materializes that is good news, but we're not we're not planning on that.
Speaker 4: transcript
Speaker 4: I think other than that, I don't think we see anything that may be meaningful that we could predict. And Brandon, I will add to the inputs that Andy just mentioned. Generally speaking, we have not deviated from our approach of coming up with the realistic, what we see in front of us in terms of the forecast and the guidance.
I think other than that.
So I don't think we see anything that maybe.
Meaningful that we could predict.
Brendan I would add to the inputs that Andy just mentioned generally speaking we have not deviated from our approach of kind of coming up with the release take what we see in front of us in terms of the forecast and the guidance.
Andy Last: And it took a while within 2023 for those effects to really roll out into our final and start to experience the deferred. Orders being pushed out. And in the other factor that no one anticipated and which was meaningful for us was the Silicon Valley Bank collapse and the knock on effects of that which really impacted the spending profile of the smaller biotech companies and we had significant trajectory in the smaller biotech for, in particular, a drop of visual PCR platform which also had some halo effects around it.
Speaker 4: transcript
Speaker 4: So I don't know that, you know, we are underestimating or overestimating our projections. And, you know, definitely the fourth quarter of this time around is an unusual circumstance in addition.
So I don't know that we are underestimating or overestimating our projections.
And therefore.
Definitely the fourth quarter. This time around is an unusual circumstance in addition to the <unk>.
Speaker 4: transcript
Speaker 4: you know, the market economy kind of environment, to end this kind of input, maybe the China environment today, I mean, I think it's going to continue well into the end of the year. So, you know, the smaller biotechnology companies environment in terms of the funding environment, I'm not expected to.
Macro economic kind of environment.
To add to Andy's kind of inputs with mainly the China environment today, I mean, I think it's going to continue well into the end of the year.
So.
The smaller biotechnology companies environment in terms of the funding environment and not expect it to.
Speaker 4: transcript
Speaker 4: improve in our mind through the end of this year. So I agree with you, historically, traditionally, the fourth quarter used to be a stronger seasonality kind of quarter for us. That is not the case this time.
Improve in horror.
Andy Last: So, you know, I think it took a couple of quarters for those effects to really materialize for us because our profiles are a little different to some of the other players. So that's how I view it and then of course since then spending is not improved or to push outs have continued and it's very difficult to gauge, you know, the true inflection point right now and I think that's probably a message that's coming across broadly from other players in the category as well.
Our mind through the end of this year.
So I agree with you historically traditionally the fourth quarter used to be a stronger seasonality kind of quarter for us.
That is not the case this time around.
Yes.
Okay.
Speaker 8: transcript
Speaker 8: Last one, I'll jump back in the queue. Andy, given you and Alon started a biorad around the same time, you've worked very closely together. You've both been instrumental to biorads transformation last four years or so. And my fifth departure, I think investors would like to know, are you happy with the operational direction of the company? Are you adequately incentivized to say the course or do you have an eye to retire?
Last one I'll jump back in the queue Andy.
I've given you an aligned started buyer at around the same time, we've worked very closely together.
Instrumental to buyer rates transformation.
Last four years or so.
<unk> his departure I think investors would like to know are you happy with the operational direction of the company are you adequately incentivize to stay the course or do you have an eye to.
Simon May: This is Simon, maybe I'll just ask for that as well because as we look at our funnels and we look at our wind loss ratios across the portfolio, whether you're talking about western bloc or gene expression or digital PCR or our bioprocess business, we really don't see any significant shifts there. We know obviously the conditions in China and Bioparma have really deteriorated but the feedback that we consistently get from the field is that there's still a high level of interest in the products, the products that we've launched have been really well received and again the funnel dynamics in terms of wind loss ratios are not seeing any significant shifts.
Two retiring anytime soon.
Speaker 3: transcript
Speaker 3: Yeah, for us and thanks. And first can I just say I'm really sad to see Elan move on and you're right. We have worked extremely closely. I, you know, I really tell his offices virtually every day. So it's been a really good journey. I want to thank Elan for that. Thank you. On the call, please. But you know, my point of view right now is we started this transition.
Thanks, Brian and Thanks first can I, just say I'm really sad to see Atlanta, Myron and Youre right. We have worked extremely closely.
And I ran each other's offices virtually every day so.
It's been a really good journey I want to thank the landfill that increments in optical headwinds.
But my point of view right now as we started that transition.
Speaker 3: transcript
Speaker 3: It's not finished, you know, and the focus is really is on the transformation of the company and executing against the strategy framework which I firmly believe.
It's not finished.
And the focus really is on the transformation of the company.
Simon May: So we really do believe that this is a bunch of transient effects that are compounding and it's making for a very difficult year but I don't think there are any macro shifts in our competitive positioning in life sciences. Alon, I think the revised guide implies 4Q revenue steps up to about 700 million I believe.
Executing against the strategy framework, which I firmly believe.
Speaker 3: transcript
Speaker 3: has potential to increase operating performance for the company moving forward.
Has the potential to increase operating performance for the company moving forward.
Thank you.
Thanks Brendan.
Speaker 1: transcript
Speaker 1: Your next question comes from the line of Patrick Donnelly from City Your Line is open.
Your next question comes from the line of Patrick Donnelly from Citi. Your line is open.
Simon May: Q is usually very strong for biorempathism, a normal environment either so how do you risk is that revenue outlook, what are some of the variables that can swing that target for downward that you're keeping in mind. So Fannie, the variables that might swing that I think they're the same that the variables would really be the same that we're experiencing just a little bit more acute if China gets definitively worse than the trajectories on for example.
Speaker 9: transcript
Speaker 9: Hey guys, thanks for taking the questions. Maybe another one on the 4Q ramp, but on the margin side, you know, pretty meaningful step up from whether it's sequential or the rest of the prior part of the year. Can you just talk about the moving pieces to get to that implied margin? I think it's 16 1 1,5, 17% type margin in 4Q. Yeah, just a path to get there and then get people comfortable that that's realistic number.
Hey, guys. Thanks for taking the questions.
Maybe another one on the <unk> ramp, but on the margin side.
Part of the year.
Can you just talk about the moving pieces to get to that implied margin I think its six year and a half 17% type type margin in <unk>.
Yes, just the path to get there and get people comfortable that that's a realistic number.
Speaker 4: transcript
Speaker 4: Sure, Patrick, this is Elon, I'll start and he can chime in. But obviously, you know, on the top line, you know, we baked in kind of the updated mix with, you know, the software live sign.
Sure Hey, Patrick this is Alan I'll start and Andy can chime in.
Simon May: That would, if academia really pulled back from spending that could have an effect you know we're not expecting a Q4 budget plus this year that's not enough thinking you know if that makes you realize that's good news but we're not planning on that. I think other than that I don't I don't think we see anything that may be you know meaningful that we could predict and it ran on our way to you know the inputs that Andy just mentioned.
But obviously.
On the top line.
We baked in kind of the updated mix.
The software life science.
Speaker 4: transcript
Speaker 4: And overall, I mean, on the operating expenses, we plan to continue some of those initiatives that we have been working on. And already in the third quarter, you can see that the operating expenses came in lower on a dollar basis. So we continue to work on additional initiatives going into the fourth quarter.
And overall I mean.
On the operating expenses.
We plan to continue some of those initiatives that we have been working on and.
Already in the third quarter, you can see that the operating expenses came in.
Lower on a dollar basis.
So we continue to work on additional initiatives going into the fourth quarter.
Simon May: Generally speaking you know we have not deviated from our approach of kind of coming up with the realistic what we see in front of us in terms of the forecast and the guidance. Yes. So, I don't know that, you know, we are underestimating or overestimating our projections.
Speaker 4: transcript
Speaker 4: And again, overall, for the bottom line, I mean, we feel it is a realistic, you know...
And.
And again overall for the bottom line I mean, we feel it is realistic.
Projection here.
Speaker 3: transcript
Speaker 3: Yeah, my only ad was, you know, we're still folks on keeping our operating post structure as tight as possible. So volume and mix, you know, will have a decent flow through.
Miami yet.
We're still focused on keeping our operating cost structure types as tight as possible. So the volume and mix will have.
Simon May: And, you know, definitely the fourth quarter of this time around is an unusual circumstance in addition to the, you know, the market economic kind of environment, to end this kind of inputs, mainly the China environment today. I mean, I think it's going to continue well into the end of the year. So, you know, the smaller biotechnology companies and environment in terms of the funding environment, I'm not expected to, you know, improve in our mind, you know, through the end of this year.
There is some flow through.
Quarter.
Pricing margin.
Speaker 9: transcript
Speaker 9: Okay. And then maybe on China, you can just talk about that market, a little bit surprising to see the diagnosis piece softer as well. Can you just talk about what you're seeing? Is it various policies over there that's impacting things? It would be helpful just to get a little more to see.
Okay.
And then maybe on China, if you could just talk about that market a little bit surprising to see the diagnostics piece softer as well can you just talk about what youre seeing is it various policies over there that's impacting things it'd be helpful. Just to get a little more discussion there.
Speaker 3: transcript
Speaker 3: Okay, so the policies are clearly impacting both life science and the diagnostics side of the business.
Oh, okay. So so the policies.
Simon May: So, I agree with you, you know, historically, traditionally, the fourth quarter used to be a stronger seasonality kind of quarter for us. That is not the case, you know, these time around. Okay.
Clearly impacting about lifestyle.
The diagnostics side of the business.
Speaker 3: transcript
Speaker 3: in the United States, you know, the United China for China. There's the anti-corruption, there's volume-based pricing, and then you layer on top of that recession. And the government, I think, that is generally struggling to find the right way to...
And they have.
They're made in China for China.
The anti corruption.
Brandon Collard: Last one, I'll jump back in the queue.
Volume based pricing.
Brandon Collard: Andy, given you and Ilan started a bioretta around the same time, you've worked very closely together. You've both been instrumental to bioreads transformation last four years or so.
Then you layer on top of that recession.
And the government I think that is January is struggling to find the right way to stimulate.
Speaker 3: transcript
Speaker 3: stimulate the market. You can add in an extra effect of
Stimulate the market.
Andy Last: In light of its departure, I think investors would like to know, are you happy with the operational direction of the company? Are you adequately incentivized to say the course, or do you have an eye to retirement when we come to them? Yeah, for Andy, thanks.
Can add in an extra effect of <unk>.
Speaker 3: transcript
Speaker 3: capital markets, soft for biobarma, which was a focus for us, for expansion and growth of those pieces of our portfolio. They all have varying impact to both sides of the business. It's just been a really tough ride through China, and there's just no...
Capital markets are soft for Biopharma, which was a focus for us.
For for expansion and growth.
You got that piece of our portfolio.
They all have varying impacts to both sides of the.
Andy Last: So, first can I just say I'm really sad to see Ilan move on and you're right. We have worked extremely closely. You know, I really tell his offices virtually every day. So, it's been a really good journey. I want to thank Ilan for that. Thank you. But, you know, my point of view right now is we started this transition. It's not finished, you know, and the focus is really is on the transformation of the company and executing against the strategy framework which I firmly believe has potential to increase operating performance for the company moving forward. Thank you. Thanks, Brandon.
Of the business.
Yes.
It's just been a really tough right through China.
No.
Speaker 3: transcript
Speaker 3: Current clear reason to think that it's going to improve
Current clear reason to think that it's going to improve in Q4.
Speaker 3: transcript
Speaker 3: And on the clinical side, it just created a softest tool for our products in China and the quarter. And...
On the clinical side it just created a softer pull for our products in China.
In the quarter.
And.
And as you know.
Speaker 3: transcript
Speaker 3: And, you know, we still have had a little bit of backlog on our clinical business as we called out. Which, you know, by the end of this year, we should be roughly where we expect to be. We may finish with a very slightly elevated backlog on clinical products at the end of the year, but we're pretty much on track.
We still have had a little bit of backlog on our clinical businesses as we called out.
Which by the end of this year, we should be roughly where we expect to be it might finish where they're very slightly elevated backlog on clinical products at the end of the year.
Patrick Donnelly: Your next question comes from the line of Patrick Donnelly from City Year Line is open. Hey, guys, thanks for taking the questions. Maybe another one on the 4Q ramp, but on the margin side, you know, a pretty meaningful step up from whether it's sequential or the rest of the prior part of the year. Can you talk about the moving pieces to get to that implied margin? I think it's 60 and a half, 70% type margin in 4Q. Yeah, just a path to get there and get people comfortable that that's a realistic number.
Yeah.
We're pretty much on track relatively speaking.
Speaker 9: transcript
Speaker 9: Okay. On the diagnostic side, is it more of the instrumentation? Obviously, the DBP stuff comes up quite often with all diagnostic players. You guys seeing anything on that front yet?
Okay on the diagnostics side with more of the instrumentation, obviously, the GBP stuff comes up quite often with all diagnostic players are you guys seeing anything on that front yet.
Okay.
First a question on the volume based pricing sorry, yes, we will access kind of difficulties.
Speaker 3: transcript
Speaker 3: Oh, the volume-based pricing. Sorry, yeah, we were just having difficulty hearing. Dara, do you want to comment on B2B?
Area.
<unk> you want to comment on PPP sure.
Speaker 10: transcript
Speaker 10: Sure, you know, it's starting to impact, you know, how we navigate tender requirements. So, I think how that's translating to reality is, you know, things are a little bit slower as we're navigating, you know, how best...
Starting to impact how we navigate tender requirements. So I think well how that's translating to reality is things are a little bit slower as we're navigating how best to position the firm.
Ilan Daskal: Sure, Patrick, this is Ilan. I'll start and Andy can chime in, but obviously, you know, on the top line, you know, we baked in kind of the updated mix with, you know, the software life science. And overall, I mean, you know, on the operating expenses, you know, we planned to continue some of those, you know, initiatives that we have been working on. And already in the third quarter, you can see that, you know, the operating expenses came in, you know, lower on a dollar basis.
For new units for new deal consideration, but value based pricing now it has historically been applied to other sectors, but in a couple of provinces. We are starting to see it reach into diabetes. So I think right now to sort of impacting our forward looking.
Speaker 10: transcript
Speaker 10: but value-based pricing, it has historically been applied to other sectors, but in a couple of provinces, we're starting to see it.
Speaker 10: transcript
Speaker 10: So, I think right now it's just sort of impacting sort of forward-looking risk, and then as Andy said, you know, we're still working on that.
And then as Andy said, you know, we're still working through that.
Speaker 10: transcript
Speaker 10: called the disturbed
Supply chain fulfilled.
Fulfillment challenges in backlog, which which were.
Speaker 10: transcript
Speaker 10: ways a bit towards that region as well and we're working through that and have that line of sight for a really solid...
Weighted towards that region as well and we're working through that and have line of sight for a really solid Q4 landing.
Ilan Daskal: So we, you know, we continue to work on additional initiatives going into the fourth quarter. And again, overall, for the bottom line, I mean, we feel it is a realistic, you know. Projection here. Yeah, Mayani had with, you know, with, who's still focused on keeping our operating cost structure as tight as, as tight as possible. So, so volume and, uh, mix, you know, we'll have a, you know, a decent flow through all the core to operating. Okay.
Okay, and maybe last one just on the PCR side, you guys called out in Q PCR weakness it seemed like DD PCR stepped down as well.
Speaker 9: transcript
Speaker 9: Okay. And maybe last one, just on the PCR side, you know, you guys called out, I think QPCR weakness, it seemed like DDPCR stepped down as well. Can you just talk about what you're seeing in that market? Is it just a broader slowdown? Is it specific, specific pockets there would be?
Talk about what Youre seeing in that market is it just a broader slowdown in specific specific pockets there would be would be helpful.
Speaker 7: transcript
Speaker 7: I think again it's a compounding issues that we've already touched on here so we've obviously got a fairly significant...
I think again, it's a compounding issues that we've already touched on here. So we've obviously got a fairly significant Q PCR digital PCR footprint in Biopharma and again the slow down.
Speaker 7: transcript
Speaker 7: QPCR, digital PCR, footprint, bi-farmer, and again the slow down.
Ilan Daskal: And then maybe on China, you know, if you could just talk about that market, you know, a little bit surprising to see the diagnosis piece softer as well. Can you just talk about what you're seeing? Is it various policies over there that's impacting things? It would be helpful just to get a little more discussion there. Oh, okay. So, so the policies, I mean, are clearly impacting both life science and the diagnostics side of the business.
Speaker 7: transcript
Speaker 7: In early biotechs, we've seen a continuation of layoffs and project referrals. That's in part to the business. We've got the COVID compare. We've got all the challenges in China that we've already talked about. And I think on top of everything else, there's kind of a glut of systems out there in the market that were placed in the pandemic. And there's a bit of free capacity out there.
The biotechs, we've seen a continuation of layoffs and project deferrals that some parts of the business. We felt the Kobe with got all the challenges in China that we've already talked about and I think on top of everything else is kind of a glut of systems out there in the market that would place didnt upon that may occur that's just been a freak.
Seattle.
Speaker 7: transcript
Speaker 7: So you roll all of these things together. Again, we refreshed our QPCR platform over the last couple of years. And again, the feedback that we get from out in the field is really positive.
So you roll all of these things together again, we refreshed our Q PCR platform over the last couple of years and again the feedback that we get from out in the field just really positive in terms of how these products are being received in the market, but this compounding of market conditions right now is adding up.
Ilan Daskal: And they have, you know, the made in China for China. There's the anti-corruption, there's volume phase pricing and then you layer on top of that recession. And the government, I think that is generally struggling to find the right way to, to stimulate, stimulate the market, you can add in an extra effect of capital markets. It's soft for biobarma, which was a focus for us for expansion and growth of those pieces of our portfolio. You know, they all have varying impact to both sides of the, of the business.
Speaker 7: transcript
Speaker 7: in terms of how these products are being received in the market. But this compounding of market conditions right now is what's adding up to its own environment.
So it's sort of environment.
Alright.
Speaker 3: transcript
Speaker 3: May I just add one extra comment, you know, you look for the silver lining on occasion and the customer demand in small biotech, the desire to take in digital PCR in particular remains very strong. What we're actually experiencing is the deferral of when they're going to make the purchase.
One extra comments.
You look for a silver lining on occasion.
Our customers demand in that.
Small biotech biopharma the desire to tech and digital PCR in particular remains very strong what were what were actually experiencing.
And when they're going to make the purchase.
Speaker 3: transcript
Speaker 3: you know, because they're constrained on cash expenditure and some other changes going on structurally.
Because they are constrained on.
Ilan Daskal: You know, it's just been a really tough ride through China and there's just no current clear reason to think that it's going to improve. And on the clinical side, it just created a soft up pool for our products in China and in the quarter and, and, and, you know, we still have had a little bit of backlog on our clinical business as, as we called out, which, you know, by the end of this year, we should be roughly where we expect to be.
Kind of a cash expenditure and some other changes going on structurally on the comp program focus.
Speaker 3: transcript
Speaker 3: So the demand side remains very encouraging.
So the demand side.
Okay.
Okay. Thanks, guys.
Thanks, Patrick.
Speaker 1: transcript
Speaker 1: Thank you. Your next question comes from the line of Jaffney Han from NEPRIN. Your line is open.
Thank you. Your next question comes from the line of Jack Meehan <unk>. Your line is open.
Thanks, Good afternoon.
Speaker 11: transcript
Speaker 11: So just want to talk about how the quarter played out here. So revenue was about 8% below the street. Can you just talk about the pacing of the quarter? Was most of the pressure you saw in September ? And is it possible there are any orders that flipped into 4Q for any reason?
So just wanted to talk about how the quarter played out here. So revenue was about 8% below the street.
Ilan Daskal: We might finish with a very slightly elevated backlog on, on clinical products at the end of the year, but we're pretty much on track relative to that. OK, on the diagnostic side, more of the instrumentation, obviously the DVP stuff comes up quite often with, with all diagnostic players. Do you see anything on that front yet? Oh, the volume by price. Sorry, yeah, we had to spend a difficult area. Is there anyone's coming on, on BPP?
Can you just talk about kind of the pacing of the quarter was most of the pressure you saw in September and is it possible there or any orders that slipped into <unk> for any reason.
Speaker 4: transcript
Speaker 4: I think Jack Heidi Huzieland, the way to think about it, I think we saw it throughout the quarter, but it accelerated towards the end of the quarter. So the pace was kind of, for decline was stronger towards the end of the quarter.
I think Jed because ilan.
To think about it I think we saw it throughout the quarter, but it accelerated towards the end of the quarter. So the pace was kind of decline was stronger towards the end of the quarter.
Speaker 4: transcript
Speaker 4: But what throughout the quarter it started to get weaker and weaker, but definitely accelerated You know
But what throughout the quarter, it started to get weaker and weaker but definitely it accelerated.
Towards the end.
Speaker 11: transcript
Speaker 11: And Norman, I know you mentioned in your comment.
Okay.
Ilan Daskal: Sure. You know, it's starting to impact, you know, how we navigate tender requirement. So I think we have that translating to reality is, you know, things are a little bit slower as we're navigating, you know, how best the position for new, for new, for new deal considerations, but value-based pricing, you know, it has historically been applied to other sectors, but in a couple of provinces, we're starting to see it, you know, reach into, to IBD.
Norman I know you mentioned in your comments.
Speaker 11: transcript
Speaker 11: There's potential for maybe a couple more bumps in the road along the way. I think there's a debate amongst tools investors around, you know, we further through the cutting cycle or, you know, could there be kind of new risks ahead because of some of the changes in the funding environment for customers. Just curious like, you know, maybe like what you're seeing through October , you know, do you, I guess like kind of what was the thinking that went behind the fourth quarter guy that you built here?
There is potential for maybe a couple more bumps in the road along the way I think there is a debate amongst tools investors around are we further through the cutting cycle or could there be kind of new risks ahead because of some of the changes in the funding environment for customers just curious like.
Maybe like what Youre seeing through October.
Ilan Daskal: So I think right now it's just sort of impacting sort of forward looking risk. And then as Andy said, you know, we're still and working through some supply chain fulfillment challenges and backlog, which were, you know, waved a bit towards that region as well. And we're working through that and have one site that's really solid to keep for landing.
I guess like kind of.
What was the thinking that went behind the fourth quarter guide that you built here.
Well I think certainly in terms of the fourth quarter guide, we looked very carefully at kind of the order book and the funnel of sales funnel kind of accumulating as much data as we can.
Speaker 5: transcript
Speaker 5: Well, you know, I think, you know, certainly in terms of the fourth quarter guide, we, you know, we looked very carefully at kind of the order book and the funnel, the sales funnel kind of accumulating as much data as we can to get the best assessment of where we think we'll land for the year. You know, when I think about bumps in the road, you know, I think about, you know, that you know,
Simon May: Okay, and maybe last one, just on the PCR side, you guys called out, I think QPCR Weekend Institute, like DDPCR, stepped down as well. Can you just talk about what you're seeing in that market? Is it just a broader slowdown? Is it specific pockets there would be helpful? I think again, it's a compounding issues that we've already touched on here. So we've obviously got a fairly significant QPCR, digital PCR footprint in biofarmer.
The best assessment.
Where we think we'll land for the year.
When I think about it bumps in the road and I think about.
That.
Speaker 5: transcript
Speaker 5: I think there were a lot of people that kind of thought the pandemic is over and everything will be back to normal next week.
I think there were a lot of people that.
They kind of thought the pandemic is over and everything will be back to normal next week.
Speaker 5: transcript
Speaker 5: And I think we're seeing a continuation of that with some of this bioforma meltdown and the re-injustments that are being made in some of these programs. I think we just have to be careful about, you know,
And.
And I think we're seeing a continuation of that with.
With some of this kind of Biopharma meltdown in the readjustments that are being made in some of these programs.
Simon May: And again, the slowdown in early biofacts, we've seen the continuation of the layoffs and project referrals, that's in part to the business. We've got the COVID compare, we've got all the challenges in China that we've already talked about. And I think on top of everything else, there's kind of a glut of systems out there in the market that were placed in the pandemic and there's a bit of free capacity out there.
I think we just have to be careful about.
Speaker 5: transcript
Speaker 5: about calling the end and saying, you know, there's always possible that there's something else that might bubble up.
Okay about calling the end and saying.
There is always possible that there is something else that that might bubble up.
Speaker 11: transcript
Speaker 11: understood. Okay. And then on the income statement, you know, you previously talked about kind of op-x reductions. I was looking at the S-GNA line kind of on non-gap basis, it actually increased a little bit sequentially and that was despite kind of revenue declining sequentially. So, I was just wondering if you could talk about what happened in S-GNA in the quarter and like the room to like pull more cost out, give him the lower top line.
Understood. Okay, and then on the income statement you previously talked about kind of Opex reduction I was looking at the SG&A line kind of on a non-GAAP basis actually increased a little bit sequentially and that was despite revenue declining sequentially.
Simon May: So you roll all of these things together. Again, we refreshed our QPCR platform over the last couple of years. And again, the feedback that we get from out in the field is really positive in terms of how these products are being received in the market. But this compounding of market conditions right now is what's adding up to its own environment.
So I was just wondering if you could talk about what happened in SG&A in the quarter and like is there room to like pull more cost out.
Simon May: I mean, I just add one extra comment. You look for the silver lining on occasion. And the customer demand in that small bioseclic platformer, the desire to take in digital PCR in particular, remain very strong. What we're actually experiencing is just the deferral of when they're going to make the purchase. You know, because they can stream on kind of cash expenditure and some other changes going on structurally on the comp program focus. So the demand side remains very encouraging. Okay. Thanks, guys. Thanks, Pissed.
Lower topline.
So.
Speaker 4: transcript
Speaker 4: So usually, you know, what you see, it was a minor kind of step up, Jack, you know, usually on the fourth quarter, we see a much higher kind of step up in S-GNA, which, you know, this time around, actually, more of the initiatives that we have been working on will kick in on the fourth quarter. So we don't anticipate, you know, the traditional step up in the fourth quarter. For the third quarter, it wasn't, you know, that material.iv. motor id roads going to get all the way through 7th round. So that way, it worked. But that solver.
Usually.
It was a minor kind of step up check usually one on the fourth quarter, we see a much higher kind of step up in SG&A, which this time around actually more of the initiatives that we have been working on will kick in on the first in the fourth quarter.
So.
We don't anticipate the traditional step up in the fourth quarter.
For the third quarter it wasn't that material.
Okay. Thank you guys.
Thank you.
Speaker 12: transcript
Speaker 12: Your next question comes from the line at 10 daily from Los Pargo, your line is open. Great, thank you. So.
Your next question comes from the line of Tim Daley from Wells Fargo. Your line is open.
Jack Meehan: Thank you. Your next question comes from the line of Japanese hand from Leprenger. Line is open. Thanks. Good afternoon. So just wanted to talk about how the quarter played out here. So revenue was about 8% below the street. Can you just talk about kind of the pacing of the quarter was most of the pressure you saw in September. And is it possible there are any orders that slipped into 4Q for any reason?
Great. Thank you.
First on the process chromatography business so.
Speaker 12: transcript
Speaker 12: I think you're previously expecting down mid single to high single decline. With the update today, I'm gonna get a 13% down or so for the year, but even with that, that implies a pretty significant step up in the fourth quarter. I think almost like 80% sequential dollar increase from 3Q to 4Q. So. So.
You were previously expecting down mid singles to high singles declined with.
Jack Meehan: Um, I think Jack Heidi Huzieland, the way, you know, to think about it, I think we saw it throughout the quarter, but it accelerated towards the end of the quarter. So the pace was kind of, of the plan was stronger towards the end of the quarter. But what throughout the quarter, it started to get weaker and weaker, but definitely accelerated, you know, towards the end. Okay. And, you know, Norman, I know you mentioned, you know, in your comments, there's potential for maybe a couple more bumps in the road along the way.
What's the update today im getting to 13% down or so for the year, but but even with that that implies a pretty significant step up in the fourth quarter, because it's almost like 80% sequential dollar or dollar increase in <unk>. So first off on these numbers, but I'm kind of getting to in the right ballpark.
Speaker 12: transcript
Speaker 12: First off, are these numbers, but I'm kind of getting to in the right ballpark. And then secondly, can you help us understand the visibility confidence that.
And then secondly can you help us understand the visibility confidence.
Speaker 12: transcript
Speaker 12: You have to kind of get that big sequential step up, especially given the commentary around a slower, lower than typical seasonality for this year end.
And you have to kind of get that big sequential step up, especially given the commentary around.
Lower lower than typical seasonality for.
For this year end.
Speaker 3: transcript
Speaker 3: Yeah, hi, this is Andy. So, yeah, I think maybe it's kind of some of the math might be a little off there. I think the process, try them overall, is going to end up at a lower number. It's kind of the guidance implication there. And it's kind of like mid-team.
Yes, Hi, this is Andy so I think maybe the.
Kind of some of the math might be a little off there.
I think the process crime overall.
It's going to it.
Jack Meehan: I think there's a debate amongst tools, investors around, you know, we further through the cutting cycle or, you know, could there be kind of new risks ahead because of some of the changes in the funding environment for customers. Just curious, like, you know, maybe like what you're seeing through October, you know, I guess like kind of what was the thinking that went behind the fourth quarter guide that you've built here. Well, you know, I think, you know, certainly, in terms of the fourth quarter-guide, we, you know, we looked very carefully at kind of the order book and the funnel, the sales funnel, kind of accumulating as much data as we can to get the best assessment of where we think we'll land for the year.
It's going to wind up at a lower non buckets and kind of the guidance implication there.
And.
It's kind of like mid teens.
Speaker 3: transcript
Speaker 3: So I don't think we're seeing a meaningful step up in process, croming Q4, but...
And so I don't think we're seeing a meaningful step hopkins process from in Q4.
Hum.
Speaker 3: transcript
Speaker 3: Yeah, I think that's really probably just a bit of math there. It's slightly higher.
Yes, I think Thats really probably is just a bit of math there is slightly higher.
Speaker 12: transcript
Speaker 12: All right, you got it. That's helpful. And then Andy, can you, you know, the supply chain impacts weighing on the third quarter diagnostic revenues? Can you just provide some detail then, like what is that, how big the impact was in the quarter? And if you expect those delayed revenues to be fully recuperated in fourth quarter?
Alright got it that's helpful.
And then Andy can you.
Fly chain impacts.
Weighing on the third quarter diagnostics revenues can you just provide some details on like what is that how big the impact was in the quarter and you expect those delayed revenues to be fully recuperated in fourth quarter.
Speaker 3: transcript
Speaker 3: Yeah. So essentially, you know, if obviously we've been communicating supply chain challenge on the clinical side because...
Jack Meehan: You know, when I think about bumps in the road, you know, I think about, you know, the, I think there were a lot of people that kind of thought the pandemic is over and everything will be back to normal next week, and you know, I think we're seeing a continuation of that with some of this kind of bioform of meltdown and the re-injustments that are being made in some of these programs, you know, it just, I think we just have to be careful about, you know, about calling the end and saying, you know, there's always possible that there's something else that that might bubble up. Understood.
Yeah.
So essentially obviously, we've been communicating our supply chain challenge on the clinical side.
Speaker 3: transcript
Speaker 3: It aids, you know, various impacts of COVID-19, plus we moved our plants from France to Singapore. We're catching up quickly, but it's sometimes difficult to get the pacing of that right. So if you get a bit of delay, you also get a bit of pull-through, consumable pull-through delay as well.
Very.
Various effects of cargo cluster move dot plots.
From from Singapore, where.
We're catching up quickly, but complex difficult to get the pacing of that right. So cute. So if you've got a bit of a delay as you will get a bit of pull through consumable pull through July as well.
Speaker 3: transcript
Speaker 3: And so that's back for the bit in to our Q3. But we are looking at a um... pretty strong Q4 and we have good line of sight now.
And so that's back to the best in to our Q3, but we are looking at a.
Pretty strong Q4, and we have good line of sight now.
Applause, Singapore is really cranking, we've got a lot of work.
Speaker 3: transcript
Speaker 3: Our plant on Singapore is really cranking. We've done a lot of work, leading out the workflows there. And so we're gonna get the benefit of that in Q4 and also get some pull through effects. So Q3s are suspended up being softer as a result over.
Jack Meehan: Okay, and then on the income statement, you know, you previously talked about kind of op-x reductions, I was looking at the SG&A line kind of on non-gap basis, it actually increased a little bit sequentially and that was despite kind of revenue declining sequentially. So, just wondering if you could talk about what happened in SG&A in the quarter and like the room to like pull more cost out in the lower top line.
Leaving out.
<unk>.
And so we're going to get the benefit of that in Q4 and also get some pull through effect. So Q3, just ended up being softer as a result overall.
Speaker 12: transcript
Speaker 12: All right, thank you. And then, you know, final one here for Norman.
Alright, Thank you and then final one here for Norman.
Speaker 12: transcript
Speaker 12: With the 23 guidance now, 400 basis points lower, that midterm cagger for 2025, the guidance updated in May now has an incremental 100 basis points or so, steeper, like it's headwind in front of it. So given the current environment, how are you evaluating the 2025 target? Or is this something that maybe we'll wait until a new CFO is in the seat to put their own fingerprints on?
With the 23 guidance now 400 basis points lower.
Mid term CAGR for 2025, the guidance update it in May now has an incremental 100 basis points or so steeper.
Jack Meehan: So usually, you know, what you see, it was a minor kind of step up, Jack, you know, usually on the fourth quarter, we see a much higher kind of step up in SG&A, which you know, this time around, actually, more of the initiatives that we have been working on will kick in on the fourth quarter. So, we don't anticipate, you know, the traditional step up in the fourth quarter. For the third quarter, it wasn't, you know, the material. Okay, thank you guys. Thank you.
I guess headwinds in front of it so given the current environment. How are you evaluating the 2025 target.
Or is this something that maybe will.
Wait until a new CFO in the seat to put their own.
Fingerprints are on every well.
Speaker 4: transcript
Speaker 4: So team, this is Ilana Chameen and then, you know, Norman Broly will have some additional color, but, you know, already in the prior quarter, we communicated that the 2025 targets from our perspective is kind of in an holding pattern. We would like to get more insight and visibility going into 2024 in order to shape, you know, our thinking about the 2025 targets.
So Tim this is Sheila timing and then.
Normal slowly will have some additional color but.
And already in the prior quarter, we communicated that the 2020 targets from our perspective is kind of in a holding pattern.
Andy Last: Your next question comes from the line of Team Daily from Los Bargo, your line is open. Okay, thank you. So, first on the process chromatography business. So, I think you're previously expecting down mid-single to high single decline. With the update today, I'm going to 13% down or so for the year, but even with that, that implies a pretty significant step up in the fourth quarter. I think almost like 80% sequential dollar increase in 3Q to 4Q. So, first off, are these numbers that I'm kind of getting into in the right ballpark?
We would like to get more insight and visibility going into 2024 in order to shape, our thinking about the 2025 targets so probably.
Speaker 4: transcript
Speaker 4: So probably, you know, in the next panel trainings call early next year, when we have the 2024 panel guidance in front of us, the 2025 numbers, you know, we will know how to think about it and to see what is the reason impact and what magnitude, et cetera. I don't know.
In the next kind of earnings call early next year.
When we have the 2024 kind of that guidance in front of us.
The 2025 numbers.
We will know how to think about it in and to see what is the reason impact and what magnitude et cetera.
I don't know.
Andy Last: And then secondly, can you help us understand the visibility confidence that you have to kind of get that big sequential step up, especially given the commentary around, you know, a slower or lower than typical seasonality for this year end? Yeah, hi, this is Andy. So, yeah, I think maybe it's kind of some of the math might be a little off there. I think the process chrom overall is going to, it's going to end up at a lower number.
I think that covers it pretty well.
Speaker 12: transcript
Speaker 12: Okay, great. Well, along great working with you. Hope you all the best from the next endeavor and thanks everybody for the time.
Okay, great well along great working with you Hope you all the best in the next endeavor and thanks, everybody for the time.
Thanks, Tim Likewise.
Speaker 1: transcript
Speaker 1: Thank you. Your next question comes from the line of Connor Matimerra from RBC Capital, your line is open.
Thank you. Your next question comes from the line of Conor Mcnamara from RBC capital. Your line is open.
Speaker 13: transcript
Speaker 13: Hi guys, thanks for taking the questions. Just...
Hi, guys. Thanks for taking the questions.
Yes.
Speaker 13: transcript
Speaker 13: without getting into 2024 guidance, how should we think about 2024 in general and just which headwinds that you called out in this quarter likely to persist in 2024 and which are likely to end by the end of this year?
Without getting into 2020 guidance.
Should we think about 2024 in general and just which headwinds that you've called out in this quarter are likely to persist in 2020 flooring, which are.
Andy Last: It kind of is the guidance implication there. And it's kind of like mid-team, and so I don't think we're seeing a meaningful step-up in process crumming Q4, but yeah, I think that's really probably just a bit of math there. It's slightly higher. All right, you got it. That's helpful.
Likely to.
And by the end of this year okay.
Speaker 4: transcript
Speaker 4: Hick on or this is ill. So I can start, you know, what obviously various aspects that are associated with the macroeconomic, you know, I'm not sure personally that, you know, China will recover like in a few weeks.
Hey, Conor this is Sheila so I can start with obviously.
Various aspects that are associated with the macroeconomic.
Im not sure personally that China will recover like in a few weeks, so that may take a little bit longer.
Speaker 4: transcript
Speaker 4: So that may take a little bit longer. The funding environment, which is obviously indirectly linked to the Treasury yield.
The funding environment, which is obviously indirectly linked to the treasury yield.
Andy Last: And then, Andy, can you, you know, display chain impacts weighing on the third quarter, diagnostics revenues? Can you just provide some detail then like what is that? How big the impact was in the quarter? And if you expect those delayed revenues to be fully recuperated in fourth quarter? Yeah, so essentially, you know, obviously we've been communicating supply chain challenge on the clinical side because, you know, various impacts of COVID plus removed our plants from France, the Singapore.
Speaker 4: transcript
Speaker 4: He's here to stay the inflationary environment is here to stay for a while So that does and probably will continue for for a while to have some impact on the smaller biotechnology companies funding
He is here to stay the inflationary environment is here to stay for a while.
So that does and probably will continue for a while to have some impact on the smaller biotechnology companies funding and the way they think about the pace of their spend so so these are definitely areas that.
Speaker 4: transcript
Speaker 4: and the way they think about the pace of their spend. So these are definitely areas that we want to kind of think about it, to think about. And then not to mention the geopolitical everywhere now that is getting kind of...
But we want to kind of think about it to think about and then.
And not to mentioned the geopolitical everywhere now.
Andy Last: We're catching up quickly, but it's, you know, sometimes difficult to get the pacing of that right. So, you know, if you get a bit of delay, you also get a bit of pull-through, consumable pull-through delay as well. And so that's back for the bit in to our Q3, but we are looking at a pretty strong Q4, and we have good line of sites now, our plant in Singapore is really cranking. We've done a lot of work leading out the workflows there. And so we're going to get the benefit of that in Q4 and also get some pull-through effects. So, Q3 just ended up being softer as a result overall. All right. Thank you.
He is getting kind of.
Speaker 4: transcript
Speaker 4: you know uh... in total probably a new level that we have not experienced before so there are multiple fronts there that uh... and you know when you think about Europe i mean overall for us Europe generally speaking you know is doing okay for us but when you think about the macroeconomic you know germany's probably already in a recession so uh... so it's going to be interesting i mean specifically that domestically we're going into you know an election year domestically so uh...
In total probably a new level the level that we have not experienced before so there are multiple fronts, there that and when you think about Europe I mean overall for US Europe generally speaking is doing okay for us, but when you think about the macroeconomic Germany's probably already in a recession. So.
So it's going to be interesting coming in specifically the domestically we're going into.
<unk> here domestically so we.
Speaker 4: transcript
Speaker 4: will have to wait and see how everything will shape up, but it doesn't have to do anything with our own kind of organic initiatives, products, new products, the end markets that are not these opinions are not going anywhere. So it's only, from my perspective, only a time.
We will have to wait and see how everything would shape up but it doesn't.
It doesn't have to do anything with our own kind of organic initiatives.
New products.
And markets that.
<unk> are not disappearing and not going anywhere so Tony from my perspective, only a timing issue.
Ilan Daskal: And then, you know, the final one here for Norman. With the 23 guidance now, 400 basis points lower, you know, that midterm cagger for 2025, the guidance updated in May now has an incremental 100 basis points or so, steeper, like it's headwind in front of it.
Speaker 13: transcript
Speaker 13: Okay, great. And just following up to Patrick's question about PCR, can you just talk about DDPCR specifically? Because that slowdown was worse than any of your other business units. So, can you give investors some framework to think about how we can get comfort that that's definitely a market environment and not competitive pressure? Because there have been some competitors out there making some noise. So we just want to make sure that you still feel good about your market position there in DDP.
Okay, great and.
And just following up to Patricks question about PCR can you just talk about DD PCR, specifically because that slowdown was worse than.
Any of your other business units. So how do we can you give investors some.
Ilan Daskal: So given the current environment, how are you evaluating the 2025 target, or is this something that maybe we'll wait until a new CFO is in the seat to put their own fingerprints on as you will? So team, this is Ilana Chameen, and then, you know, Norman Broly will have some additional color. But, you know, already in the prior quarter, we communicated that the 2025 targets from our perspective is kind of in an holding pattern.
We work to think about how how is that how we can get comfort that thats definitely a market environment and not competitive.
Pressure because there have been some competitors out there, making some noise. So just want to make sure that you still feel still feel good about your market position, there and DD Pcr.
Speaker 7: transcript
Speaker 7: I still think we've feel good about the position. I mean, we've made no secret of the fact that the compactive landscape is insensitive by. And as we reflect on Q3, I think as we call out in the scripts, we've had a couple of really notable wins that that we think are gonna help continue to position us well for the future. I think what we really saw in Q3, again, is an exacerbation of these bi-farmering packs. We have particular strengths.
I still think we feel good about our position I mean, we've made no secret of the fact.
The competitive landscape is essentially volume.
As we reflect on Q3, I think because we called out in the script. We had a couple of really notable wins that we think are going to help continue to position us well for the future I think what we really saw in Q3 again, it's an exacerbation of the spot pharma written pox, we have particular.
Ilan Daskal: We would like to get more insight and visibility going into 2024 in order to shape, you know, our thinking about the 2025 targets. So probably, you know, in the next kind of earnings call early next year, when we have the 2024 kind of guidance in front of us, the 2025 numbers, you know, we'll know how to think about it and to see what the reason in person will make it to you that's in our own.
Strength in.
Speaker 7: transcript
Speaker 7: in the early biotech sector, and I think what we saw in Q3 was a cumulative impact of these deferred projects and layoffs in the continuing extremely tight budget environment. Once again, we're seeing a lot of interest in the products, but the money is just not flowing. We continue to see healthy adoption and really strong acceptance of our QX600 platform.
The early buyouts at sites.
And I think what we saw in Q3 was the cumulative impact of these deferred projects and write offs and the continuing extra.
STREAMWAY solid budget environment. Once again, we're seeing a lot of interest in the products, but the money is just not flowing we continue to see healthy adoption really strong acceptance of our <unk> 600 platform. So as we look to the future. If we all believe that these impacts in biopharma are transient and when we emerge from it we think we're going to be.
Norman Schwartz: I don't know. No, I think so. I think so, is it pretty well.
Operator: Okay, well, along great working with you. Hope you all the best from the next endeavor, and thanks everybody for the time. Thanks, team, life boys. Thank you.
Speaker 7: transcript
Speaker 7: So we're looking at the future if we all believe that these impacts in biopharmoratrancy and then when we emerge from it we think we're going to be in a really strong position. And then of course we've got competitors who are playing more in the lower end segments and we plan to enter there with the QXC continue and platform in 2020.
Conor Mcnamara: Your next question comes from the line of Conor Matamera from RBC Capital, your line is open. Hi, guys. Thanks for taking the questions.
A really strong position and then of course, we've got competitors, who are playing more in the lower end segments and we plan to enter with the Qs continuum platform in two.
Ilan Daskal: Just without getting into 2024 guidance, how should we think about 2024 in general and just which headwinds that you called up in this quarter likely to persist in 2024 and which are likely to end by the end of this year? Hi, Conor. This is Ilan. So I can start with various aspects that are associated with the macroeconomic. I'm not sure personally that China will recover in a few weeks, so that may take a little bit longer.
2024, so for sure the competitive pressure is essentially volume I think we've got compelling responses.
Speaker 7: transcript
Speaker 7: So for sure the competitive pressure is intensified, but I think we've got compelling responses. And where we've got leading positions in these segments will continue to do well as and when these markets recover.
Where we've got leading positions in these segments will continue to do well awesome when these markets recover.
Speaker 13: transcript
Speaker 13: Great, thanks for that time. And just a quick follow up on pricing. And I guess this is a press, everything in life sciences. You know, what's the pricing environment like? And how should we think about that billing forward?
Great. Thanks for that Simon just a quick follow up on pricing and I guess this is across everything in life Sciences.
What's the pricing environment like and how should we think about that going forward.
Yes, I think that.
Speaker 3: transcript
Speaker 3: Yeah, I think that, you know, the environment is still inflationary, as you probably appreciate, on the clinical side of, you know, tender-driven business, you can only take very modest and periodic price increases, and we do that when we get that opportunity.
Ilan Daskal: The funding environment, which is obviously indirectly linked to the Treasury yield is here to stay. The inflationary environment is here to stay for a while, so that does and probably will continue for a while to have some impact on the smaller biotechnology companies funding and the way they think about the pace of their spend. So these are definitely areas that we want to think about it, to think about and then not to mention the geopolitical everywhere now that is getting kind of to probably a new level that we have not experienced before.
The environment is still inflationary.
Appropriate appreciated on our on the political side tender driven business.
You cannot take very modest periodic price increases.
We do that when we get when we get that opportunity.
Speaker 3: transcript
Speaker 3: Unlike science, there is still an inflationary effect and we will still look to try and take modest prices.
On life Science.
Or is there is still an inflationary effect.
Yes.
We'll still look to try and take modest price increases as we move forward.
Speaker 3: transcript
Speaker 3: forward to help offset our inflationary pressures that we're receiving.
So to offset inflationary pressures that we're receiving.
Speaker 3: transcript
Speaker 3: And I will expect to do, we've done that this year, we expect to do that. Next year, I think in the quarter we probably got, you know, I've just over a point of price, point point in a half of price on the net.
And I would expect to do we've done that this year, we expect to do that.
Jeremy I think in the quarter, we probably just over a point of price points in the half with price on a net basis.
Ilan Daskal: So there are multiple fronts there that when you think about Europe, I mean overall for us, Europe, generally speaking, is doing okay for us. But when you think about the macroeconomic, Germany is probably already in a recession, so it's going to be interesting. Specifically, that domestically we're going into an election year domestically, so we'll have to wait and see how everything will shape up, but it doesn't have to do anything with our own kind of organic initiatives, new products, the end markets that are not disappearing, they're not going anywhere.
Speaker 3: transcript
Speaker 3: and I think that that should at least be a flaw.
And I think that that should at least be a floor.
We've seen a mix impact that we process as well.
Speaker 7: transcript
Speaker 7: We've seen a mixed impact there with processed chrome as well.
Yes.
Speaker 13: transcript
Speaker 13: Okay, thanks. And just final question, this is for Norm. Just given the recent sell off in the space and specifically in your stock, you know, how does how does that change your acquisition strategy, if at all? And would you still considering would you still consider issuing equity to pursue an acquisition target in this environment?
Okay. Thanks, and then just.
Final question list for norm.
Just given the recent sell off in the space and specifically in your stock how does that how does that change your acquisition strategy. If at all and would you still considering would you still consider issuing equity to pursue.
When acquisition targets in this environment.
Simon May: So it's only from my perspective, only a timing issue. Okay, great.
Speaker 5: transcript
Speaker 5: So I think that in light of the recent stock dislocation, I think we will very much consider continuing our share repurchases as part of our capital allocation strategy. And obviously, at this point, not such a good currency for M&A.
So I think that kind of in light of the recent stock.
Location I think.
Simon May: And just following up to Patrick's question about PCR, can you just talk about GDPCR specifically, because that slowed down on worse than any of your other business units. So, you know, how do we, can you give investors some, you know, framework to think about how that, how we can get comfort that that's definitely a market environment and not competitive pressure, because there have been some competitors out there making some noise, we just want to make sure that you still feel, still feel good about your market position there in GDPCR.
We were very much consider continuing our share repurchases.
Part of our capital allocation strategy.
Obviously at this point not such a good currency.
Four.
For M&A.
Speaker 5: transcript
Speaker 5: I think in fact, you know, you know, what we do continue to kind of look at opportunities, I think it's probably fair to say that more of our focus over the next several quarters will be centered around, you know, kind of navigating our markets and our continued operational transformation.
I think in fact.
Well we are.
While we do continue to kind of look at opportunities I think it's probably fair to say that more of our focus over the next several quarters will be centered around.
Simon May: I still think we feel good about the position. I mean, we've made some secret of the fact that the competitive landscape is insensitive by, and as we reflect on Q3, I think as we call down in the scripts, we've had a couple of really notable wins there that we think are going to help continue to position as well for the future. I think what we really saw in Q3, again, as an exacerbation of these biopharma impacts, we have particular strengths in the early biotech sector, and I think what we saw in Q3 was the cumulative impact of these deferred projects and layoffs and the continuing extremely tight budget environment.
Kind of navigating our markets.
And our continued operational transformation.
Speaker 13: transcript
Speaker 13: Great. Thanks for the time, and thanks for the questions you guys, and along we wish you the best of luck, and it's been a pleasure and a pleasure. Thank you for all.
Great. Thanks.
Thanks for the time, thanks for the questions you guys along we wish you the best of luck and it's been a pleasure working with you.
Thank you Conor I appreciate it likewise.
Speaker 1: transcript
Speaker 1: There are no further questions at this time. I would like to turn it back to Edward Choon for further remarks.
There are no further questions at this time I would like to turn it back to Ed Mitchell for further remarks.
Speaker 2: transcript
Speaker 2: Thank you for joining today's call. As always, we appreciate your interest and we look forward to connecting soon. Thanks, operator.
Thank you for joining today's call as always we appreciate your interest and we look forward to connecting soon thanks operator.
Speaker 1: transcript
Speaker 1: Thank you. And ladies and gentlemen, this concludes today's conference call. Thank you for participating in eNOW Disconnect.
Thank you and ladies and gentlemen. This concludes today's conference call. Thank you for participating you may now disconnect.
Simon May: Once again, we're seeing a lot of interest in the products, but the money is just not flowing. We continue to see healthy adoption and really strong acceptance of our QH600 platform. So, as we look at the future, if we all believe that these impacts in biopharma are transient, and when we emerge from it, we think we're going to be in a really strong position. And then of course, we've got competitors who apply more in the lower end segments, and we plan to enter there with the QH's continuing platform in 2020, for.
Okay.
This conference call. Thank you for participating.
Simon May: So for sure, the competitive pressure is intensifying, but I think we've got compelling responses and where we've got leading positions in these segments will continue to do well as in when these markets recover. Great, thanks for that, Simon.
Simon May: And just a quick follow-up on pricing, and I guess this is across everything in life sciences. You know, what's the pricing environment like and how should we think about that building forward? Yeah, I think that, you know, the environment is still inflationary as you probably appreciate Conor on the clinical side, you know, tender driven business. You cannot take very modest and periodic price increase. And we do that when we get when we get that opportunity.
Simon May: Unlike science, the, you know, there is still inflationary effect and, you know, we will still look to try and take modest price increases as we move forward to help offset our inflationary pressures that we're receiving. And, you know, we expect to do, we've done that this year, we expect to do that next year, and I think in the corner we probably got, you know, just over a point of price, point point in a half of price on a net basis. And I think that that should at least be a flaw. We've seen a mixed impact that we've processed Chrome as well. Yeah. Okay. Thanks.
Norman Schwartz: And just final question, this for Norm, just given the recent sell-off in the space and specifically in your stock, you know, how does that change your acquisition strategy, if at all, and would you still considering, would you still consider issuing equity to pursue an acquisition target in this environment? So I think that, you know, kind of in light of the recent stock dislocation, I think, you know, we will very much consider continuing our share repurchases as part of our capital allocation strategy.
Norman Schwartz: And obviously, at this point, not such a good accuracy for M&A. I think in fact, you know, what we do continue to kind of look at opportunities, I think it's probably fair to say that more of our focus over the next several quarters will be centered around, you know, kind of navigating our markets and our continued operational transformation.
Conor Mcnamara: Great. Thanks for the time. And thanks for the questions, you guys, and along we wish you the best of luck, and it has been a pleasure working with you. Thank you for our appreciate it likewise.
Edward Schoen: There are no further questions at this time. I would like to turn it back to Edward Chu for further remarks. Thank you for joining today's call. As always, we appreciate your interest and we look forward to connecting soon. Thanks, operator. Thank you.
Operator: And ladies and gentlemen, this concludes today's conference call. Thank you for participating in me now, disconnect.
Operator: This conference call, thank you for participating in me.